## Summary Table of Study Protocol

Title	A Multinational Observational Study to Evaluate the Safety of Repatha <sup>®</sup> in Pregnancy	
Protocol version identifier	2.0	
Date of last version of the protocol	17 May 2016	
EU Post Authorisation Study (PAS) Register No	EUPAS15153	
NCT Number	NCT02906124	
Active Substance	Evolocumab	
Medicinal Product	Repatha®	
Product Reference	EU/1/15/1016	
Procedure Number	EMA/H/C/3766	
Marketing Authorisation Holder(s)	Amgen Europe B.V.	
Joint PASS	No	
Research Question and Objectives	Research Question: To evaluate <b>pregnancy and infant</b> outcomes <b>among</b> females diagnosed with familial hypercholesterolaemia (FH), exposed to Repatha® during pregnancy. This includes follow-up of their infants to the age of 12 months. Primary Objective: To describe congenital anomalies in infants of females with FH exposed to Repatha® within 15 weeks prior to or during pregnancy, followed to the age of 12 months. Secondary Objectives: To describe outcomes of pregnancy (other than congenital anomalies) in females with FH exposed to Repatha® within 15 weeks prior to and/or during pregnancy; To describe outcomes of pregnancy in females with FH not exposed to Repatha® within 15 weeks prior to and/or during pregnancy; To describe health and developmental outcomes in infants up to the age of 12 months, born to females diagnosed with FH and exposed/unexposed to Repatha® during pregnancy and/or breastfeeding.	
Countries of Study	Europe (multicountry), South Africa, Australia	
Author	PPD Amgen Ltd 1 Uxbridge Business Park Sanderson Road Uxbridge UB8 1DH UK	



#### Marketing Authorisation Holder

Marketing authorisation holder(s)	Amgen Europe B.V.
MAH Contact	PPD Amgen Ltd 1 Uxbridge Business Park Sanderson Road Uxbridge UB8 1DH UK PPD

## **Confidentiality Notice**

This document contains confidential information of Amgen Inc.

This document must not be disclosed to anyone other than the site study staff and members of the Institutional Review Board/Independent Ethics Committee/Institutional Scientific Review Board or equivalent, as applicable.

The information in this document cannot be used for any purpose other than the evaluation or conduct of the research without the prior written consent of Amgen Inc.

If you have questions regarding how this document may be used or shared, call the Amgen Medical Information number: 0800 121 8703 (toll-free) or +44 1223 420305



#### Investigator's Agreement

I have read the attached protocol entitled "A Multinational Observational Study to Evaluate the Safety of Repatha<sup>®</sup> in Pregnancy", dated **18 December 2018**, and agree to abide by all provisions set forth therein.

I agree to ensure that the confidential information contained in this document will not be used for any purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of Amgen Inc.

Signature


Name of Investigator

Date (DD Month YYYY)



#### Study Design Schema

Enrolment occurs at the time of identification of the pregnancy by the study site



#### DATA ON PREGNANT MOTHERS

CONFIDENTIAL



## 1. Table of Contents

Sum	mary Ta	ble of Stu	dy Protocol		1
Study	/ Desigi	n Schema			4
1.	Table of	of Content	S		5
2.	List of a	Abbreviati	ons		8
3.	Respo	nsible Par	ies		9
4.	Abstra	ct			9
5.	Amend	lments and	d Updates		15
6.	Milesto	nes			15
7.	Rationa 7.1 7.2 7.3	Diseases Rationale	and Therape	eutic Area Estimation or Hypothesis)	15 17
8.	Resear 8.1 8.2	Primary C	bjective	ctives	18
9.	Reseat 9.1 9.2	Study De Setting an 9.2.1 9.2.2 9.2.3 9.2.4 9.2.5 9.2.6	sign ad Study Pop Study Period Selection an Subject Eligi 9.2.3.1 I 9.2.3.2 E Matching Baseline Per Study Follow s - Variables Exposure As Outcome As Covariate As	oulation d d Number of Sites ibility Inclusion Criteria Exclusion Criteria riod v-up ssessment ssessment ssessment Reliability	19 19 19 20 20 20 21 21 21 21 21 21 21 21 23 24 24 24
	9.4 9.5 9.6	Data Sou Study Siz	rces e agement Obtaining Da	ata Files	25 25 26 27



		9.6.3	Review a	nd Verification of Data Quality	27
	9.7	Data An	alysis		27
		9.7.1	Planned	Analyses	27
			9.7.1.1	Interim Analyses	27
			9.7.1.2	Primary Analysis	27
		9.7.2	Planned	Method of Analysis	28
			9.7.2.1	General Considerations	28
			9.7.2.2	Missing or Incomplete Data and Lost to Follow-up	28
			9.7.2.3	Descriptive Analysis	
			9.7.2.4	Analysis of the Primary and Secondary Endpoints	29
			9.7.2.5	Sensitivity Analysis	29
			9.7.2.6	Subgroup Analysis	29
			9.7.2.7	Stratified Analysis	29
		9.7.3	Analysis	of Safety Endpoint(s)/Outcome(s)	30
	9.8	Quality	Control		30
	9.9	Limitatio	ons of the R	esearch Methods	31
		9.9.1	Informatio	on Bias	31
		9.9.2	Selection	Bias	31
		9.9.3		ns due to Missing Data and/or Incomplete	
	9.10	Other A	spects		32
10.	Protec	ction of H	uman Subie	ects	32
10.	10.1		-		
	10.2			Board (IRB)/Independent Ethics Committee	
					33
	10.3	Subject	Confidentia	llity	34
11	Collec	tion of Sc	afety Inform	ation and Product Complaints	34
			-	Events	
	11.1	11.1.1		Events	
		11.1.2		Adverse Events	
		11.1.2		fety Findings	
		11.1.4		Complaints	
	11.2			equirements	
		11.2.1		eporting Requirement to Regulatory Bodies	
12.	Admir	nistrative a	and Legal C	Obligations	
	12.1		•	nts and Study Termination	
13.	Plans	for Disse	minating an	d Communicating Study Results	
	13.1	Publicat	ion Policy		38
14.	Refere	ences			

15.	Appendices	41	
10.			

## List of Appendices

Appendix A.	List of Stand-alone Documents	42
Appendix B.	ENCePP Checklist for Study Protocols	43
Appendix C.	Sample Electronic Adverse Event Contingency Report Form	48
Appendix D.	Additional Safety Reporting Information	50
Appendix E.	EUROCAT Subgroups of Congenital Anomalies	51
Appendix F.	Pregnancy Outcome Definitions*	55
Appendix G.	Template Summary Table of Pregnancy Outcome	56
Appendix H.	Calculation of Percentage of Live Births	58
Appendix I.	Pregnancy and Lactation Worksheets	59



Abbreviation	Meaning	
СА	Competent Authority	
CETP	Cholesterylester transfer protein	
eCRF	Electronic case report form	
EMA	European Medicines Authority	
ENCePP	European Network of Centres for Pharmacoepidemiology and Pharmacovigilance	
Enrolment	Subject is considered enrolled when informed consent/notification has occurred (if applicable according to local requirements), eligibility has been determined and data entry initiated into the eCRF.	
EU PAS	European Post-Authorisation Study	
EUROCAT	European Surveillance of Congenital Anomalies	
FH	Familial hypercholesterolaemia	
ICD10-BPA	International Classification of Diseases version 10 British Paediatric Association	
ICH GCP	International Committee for Harmonisation Good Clinical Practice	
ICJME	International Committee of Medical Journal Editors	
lgG	Immunoglobulin G	
IRB/IEC	Institutional Review Board/ Institutional Ethics Committee	
LDL-C	Low density lipoprotein-cholesterol	
MAN	Manual	
PCSK9	Proprotein convertase subtilisin/kexin type 9	
SmPC	Summary of Product Characteristics	
SOP	Standard Operating Procedure	
Source data Information from an original record or certified as a copy of the original record containing patient information for use in clinical research. The information may include, but is not limited to, clinical findings, observations or other activities in a study necessary for the reconstruct and evaluation of the study. Source data are contained in source documents (original records or certified copies). (ICH Guideline E6).		
Study start	Date on which first study site is initiated	
QM	Once-monthly	

#### 2. List of Abbreviations



#### 3. Responsible Parties

Amgen Ltd is responsible for all aspects of study execution, conduct and reporting.

#### 4. Abstract

- Study Title: A Multinational Observational Study to Evaluate the Safety of Repatha<sup>®</sup> in Pregnancy
- Study Background and Rationale:

Individuals with genetic causes of hypercholesterolaemia comprise a small proportion of the dyslipidaemia population, but suffer a disproportionately high risk of experiencing a cardiovascular event. Approximately 95% of mutations exist within the low density lipoprotein (LDL) receptor and manifest with the clinical diagnosis of familial hypercholesterolaemia (FH) (Rader et al, 2003). Because LDL receptor-mediated endocytosis is the principal mode of hepatic LDL-cholesterol (LDL-C) clearance, compromised LDL receptor function often results in an increase in circulating LDL-C levels. This renders affected individuals extremely vulnerable to the consequences of severe atherosclerotic disease, such as myocardial infarction and stroke: There is a 2-fold excess of coronary heart disease-related deaths relative to age-matched controls in this population (Neil et al, 2008).

A serine protease expressed predominantly in the liver, kidney and intestine (Seidah,2003), proprotein convertase subtilisin/kexin type 9 (PCSK9), plays an important role in the recycling and regulation of the LDL receptor (Horton et al, 2007; Brown and Goldstein, 2006). PCSK9 acts via direct binding to the LDL receptor, resulting in post-translational down-regulation of receptor expression on the hepatic cell surface. This in turn leads to increased levels of circulating LDL-C. Repatha<sup>®</sup> (evolocumab) is a fully human monoclonal immunoglobulin (Ig) G2 that binds specifically to human PCSK9 and prevents the interaction of PCSK9 with the LDL receptor, thus lowering plasma LDL-C levels.

In Europe, Repatha<sup>®</sup> is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet, in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated (Repatha<sup>®</sup> EPAR, EMA website). **Repatha is also indicated in adults and adolescents aged 12 years and over with homozygous** familial hypercholesterolaemia in combination with other lipid-lowering therapies.



Additionally, Repatha is indicated in adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors: in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or, alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Based on modality, mechanism of action, and nonclinical studies, safety issues are not expected with Repatha<sup>®</sup> use during pregnancy. As a therapeutic monoclonal antibody, placental transfer during organogenesis in humans is expected to be low (DeSesso, 2012; ICH M3 (R2), 2009). Further, the conceptus derives at least 80% of its cholesterol needs from endogenous synthesis rather than from the maternal circulation (Woollett, 2005; Bartels, 2011). Independence from maternal sterol status indicates that normal fetal development would not be expected to be affected by the cholesterol lowering properties of Repatha<sup>®</sup> which are independent of effects on cholesterol synthesis. Across multiple species including humans, the rates of cholesterol synthesis in the fetus are much greater than in the adult (Dietschy et al 1993). Consistent with this, low maternal cholesterol is not causally associated with adverse birth outcomes. Whether mediated by dietary intervention or by genetic mutations, normal embryo-fetal development has been observed in children born to mothers with low cholesterol throughout pregnancy (Connor et al, 1978; McMurry et al, 1981; Homanics et al, 1993). Moreover, nonclinical studies have shown that administration of Repatha® to pregnant cynomolgus monkeys throughout gestation (at exposure levels12-times higher than patients receiving Repatha® at 420 mg once monthly (QM)) resulted in no effects on embryo-fetal/neonatal growth and development through to 6 months postpartum (Evolocumab Investigator Brochure 2015). However, clinical data of Repatha<sup>®</sup> use in pregnancy is limited, therefore safety of Repatha® in pregnancy is considered to be missing information and this is reflected in the Summary of Product Characteristics (SmPC).

The SmPC states the following on use of Repatha® in association with pregnancy:

- There are no or limited amount of data from the use of Repatha<sup>®</sup> in pregnant women. Animal studies do not indicate direct or indirect effects with respect to reproductive toxicity.
- Repatha<sup>®</sup> should not be used during pregnancy unless the clinical condition of the woman requires treatment with evolocumab.



**Similarly, s**afety of Repatha<sup>®</sup> whilst breast-feeding is considered to be missing information. Published literature **indicates that in general, there is** a low risk of maternally-administered monoclonal antibodies resulting in pharmacologically relevant systemic exposures in breastfed infants, the milk-to-serum concentration ratio of IgG being low (Kim et al, 1992; Telemo et al., 1996; Ostensen and Eigenmann, 2004; Mahadevan et al, 2005; Vasiliauskas et al, 2006). In studies of breast-feeding women treated with other therapeutic monoclonal antibodies, these antibodies were not present in breast milk at detectable concentrations (Vasiliauskas et al, 2006, Kane and Acquah, 2009). In addition, large molecules are known to have low oral bioavailability in the infant gastrointestinal tract (Van de Perre, 2003; Lobo et al, 2004; Hurley and Theil, 2011).

The SmPC states the following on use of Repatha® whilst breast-feeding:

- It is unknown whether evolocumab is excreted in human milk.
- A risk to breastfed newborns/infants cannot be excluded.

A decision must be made whether to discontinue breast-feeding or discontinue/abstain from Repatha<sup>®</sup> therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

In light of the limited data available on use of Repatha<sup>®</sup> in association with pregnancy and/or lactation, this study is being conducted in response to a request by the European Medicines Authority (EMA) to provide data on outcomes of pregnancy in women (and their infants to the age of 12 months) exposed to Repatha<sup>®</sup> prior to or during pregnancy and/or breast-feeding.

In women of child-bearing age in Europe, South Africa, and Australia those most likely to have been identified as requiring Repatha<sup>®</sup> for control of hypercholesterolaemia are those diagnosed with FH. Introduction of this particular pharmacological intervention in the majority of non-FH women is anticipated to occur beyond reproductive age.

Considering the low rate of FH diagnosis and therefore the small number of Repatha<sup>®</sup>-exposed pregnancies anticipated to occur, routine pharmacovigilance surveillance based solely on spontaneous reporting is unlikely to provide the information required by the EMA, in the post-launch period. To address this, a separate study is required, with a targeted, proactive approach to identify potential study subjects and seek appropriate follow-up on outcomes of pregnancy in women with FH who have received Repatha<sup>®</sup> during pregnancy and/or breast-feeding.

#### CONFIDENTIAL



This multinational observational study is expected to enrol female FH patients, identified in collaboration with specialist physicians and patient groups: Females with FH exposed to Repatha<sup>®</sup> during pregnancy and/or breast-feeding will form the exposed cohort, and females with FH unexposed to Repatha<sup>®</sup> during pregnancy and breast-feeding will form the internal comparator group. Although no formal comparison of exposed/unexposed subjects is planned, capturing outcomes of pregnancy in a rare population unexposed to Repatha<sup>®</sup> will provide contemporary reference **data** against which to consider outcomes in exposed pregnancies. **Due to potentially insufficient data and consequent lack of statistical power, it is unlikely that comparisons between the two groups will provide meaningful results, hence, no formal comparison of exposed/unexposed subjects is planned.** 

- Research Question and Objectives
- Primary Objective:

To describe congenital anomalies in infants of females with FH exposed to Repatha<sup>®</sup> within 15 weeks prior to or during pregnancy, followed to the age of 12 months.

- Secondary Objectives:
  - To describe outcomes of pregnancy (other than congenital anomalies) in females with FH exposed to Repatha<sup>®</sup> within 15 weeks prior to and/or during pregnancy
  - To describe outcomes of pregnancy in females with FH not exposed to Repatha<sup>®</sup> within 15 weeks prior to and/or during pregnancy
  - To describe **health and developmental** outcomes in infants up to the age of 12 months, born to females diagnosed with FH and unexposed **or exposed** to Repatha<sup>®</sup> **during pregnancy and/or breastfeeding.**
- Hypothesis:

No formal hypothesis will be tested in this study. Statistical analyses will be descriptive only.

• Study Design/Type:

Multinational prospective observational cohort study

• Study Population or Data Resource:

The study population comprises females in Europe, South Africa and Australia diagnosed with FH and who are **either** pregnant or breast-feeding during the study period, and who provide informed consent to participate in the study, **if applicable** 



according to local requirements. Their infants will also be followed to the age of 12 months, following consent by the mother (if applicable per local regulations).

(Note: The therapeutic strategy assigned to each patient enrolled in the study will not be specified within this study protocol. Instead, it will be decided according to routine clinical practice, hence the decision for medicinal prescription will be clearly dissociated from the decision to include the patient in the study).

• Summary of Subject Eligibility Criteria

Inclusion Criteria:

- Females diagnosed with FH
- Confirmed pregnancy during the study observation period
  - Pregnancies identified retrospectively but within the study period will be included
  - Multiple pregnancies, occurring in the same woman within the study period, will all be included (as separate pregnancies)
- Provided informed consent to follow-up in this study, for subject and their infant(s) born during the study observation period
- Follow-up

Subjects will be followed for outcomes of pregnancy during the study observation period, which for each individual subject will be from 15 weeks prior to pregnancy through to the end of pregnancy (ie, to birth or to loss of the pregnancy). Infants born to subjects during the observation period will be followed from birth to 12 months of age.

The study is anticipated to cover a 10-year period, from June 2016 to June 2026.

Variables

The following types of data/outcomes will be collected:

- Maternal Data:
  - Demographics
  - Current pregnancy history
  - Medical history
  - Obstetric history
  - Lipid levels
  - Medications

- Congenital anomalies
- Complications of pregnancy
- Outcomes of pregnancy
- Mode of delivery
- Complications of delivery
- Infant Data:
  - Infant status at delivery
  - Infant health, growth, and developmental outcomes until 12 months of age
- Exposure Data: Exposure to Repatha<sup>®</sup> (duration of exposure, doses, dose frequency) within 15 weeks prior to conception and/or during pregnancy and/or whilst breast-feeding

Information available for each subject on all variables will be reported by study site staff in the study-specific sponsor database. The original data source will be patient records, from routine follow-up of subjects. All data will be gathered during routine visits only.

Study Sample Size:

The study will collect data on all pregnancies and births in females diagnosed with FH and identified via the specialist centres/networks, where the patient consents to participate. Based on a conservative estimated FH prevalence of 1 in 500, and a national diagnosis rate varying between 70% and 1% (Nordestgaard 2013), the number of subjects identified for inclusion in this study is not expected to be large. The EMA quideline EMEA/CHMP/203927/2005 "GUIDELINE ON RISK ASSESSMENT OF MEDICINAL PRODUCTS ON HUMAN REPRODUCTION AND LACTATION: FROM DATA TO LABELLING" assumes an overall incidence of birth defects of 3% in order to derive the number of first trimester pregnancies exposed to a medicinal product that is needed to exclude a certain level of risk. The Guideline further states that if no increased incidence of malformations is observed within at least 300 first trimester-exposed, prospectively collected pregnancies with known pregnancy outcomes (births or fetopathological examinations) then the conclusion might be reached that the medicinal product is not responsible for a 10-fold or more increase of the overall incidence of malformations. In accordance with the Guideline, this study will endeavour to enrol 300 pregnancies exposed to Repatha in the first trimester. The maximum number of unexposed pregnancies will be limited to a ratio of 2 unexposed to 1 exposed; ie, 600 unexposed pregnancies.



Data Analysis:

Statistical analyses will be descriptive only. No statistical inference or imputations of missing data are planned.

Subject demographics and baseline characteristics will be summarised. Summary statistics for continuous variables will include the number of subjects, mean, median, standard deviation or standard error, minimum, and maximum. For categorical variables, the frequency and percentage will be reported.

#### 5. Amendments and Updates

Amendment/Update	Date Performed
Study Protocol Amendment	18 December 2018

#### 6. Milestones

Milestone	Planned date
Start of data collection	Not before June 2016 (depending on first prescriptions)
End of data collection	10 years after study start.
Feasibility report to Competent Authority (CA)	September 2019
Interim reports to CA	Annually according to the international birth date (IBD)
Registration in the EU PAS register	Before June 2016
Final report of study results to CA	Mandated within 12 months after end of data collection ie, June 2027

#### 7. Rationale and Background

#### 7.1 Diseases and Therapeutic Area

Individuals with genetic causes of hypercholesterolaemia comprise a small proportion of the dyslipidaemia population, but suffer a disproportionately high risk of experiencing a cardiovascular event. Approximately 95% of mutations exist within the low density lipoprotein (LDL) receptor and manifest with the clinical diagnosis of familial hypercholesterolaemia (FH) (Rader et al, 2003). Because LDL receptor-mediated endocytosis is the principal mode of hepatic LDL-cholesterol (LDL-C) clearance, compromised LDL receptor function often results in an increase in circulating LDL-C levels. This renders affected individuals extremely vulnerable to the consequences of severe atherosclerotic disease, such as myocardial infarction and stroke: There is a



2-fold excess of coronary heart disease-related deaths relative to age-matched controls in this population (Neil et al, 2008).

A serine protease expressed predominantly in the liver, kidney and intestine (Seidah 2003), proprotein convertase subtilisin/kexin type 9 (PCSK9), plays an important role in the recycling and regulation of the LDL receptor (Horton et al, 2007; Brown and Goldstein, 2006). PCSK9 acts via direct binding to the LDL receptor, resulting in post-translational down-regulation of receptor expression on the hepatic cell surface. This in turn leads to increased levels of circulating LDL-C. Repatha<sup>®</sup> is a fully human monoclonal immunoglobulin (Ig) G2 that binds specifically to human PCSK9 and prevents the interaction of PCSK9 with the LDL receptor, thus lowering plasma LDL-C levels.

In Europe, Repatha<sup>®</sup> is indicated in adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors: in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or, alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. Repatha is also indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies (Repatha<sup>®</sup> EPAR, EMA website). Based on modality, mechanism of action, and nonclinical studies, safety issues are not expected with Repatha<sup>®</sup> use during pregnancy. As a therapeutic monoclonal antibody, placental transfer during organogenesis in humans is likely to be low (DeSesso, 2012; ICH M3(R2), 2009). Further, the conceptus derives at least 80% of its cholesterol needs from endogenous synthesis rather than from the maternal circulation (Woollett, 2005; Bartels, 2011). Independence from maternal sterol status indicates that normal fetal development would not be expected to be affected by the cholesterol lowering properties of Repatha<sup>®</sup> which are independent of effects on cholesterol synthesis. Across multiple species including humans, the rates of cholesterol synthesis in the fetus are much greater than in the adult (Dietschy et al 1993). Consistent with this, low maternal cholesterol is not causally associated with adverse birth outcomes. Whether mediated by dietary intervention or by genetic mutations, normal embryo-fetal development has been observed in children born to mothers with low cholesterol throughout pregnancy (Connor et al, 1978; McMurry et al, 1981; Homanics et al, 1993).



Moreover, nonclinical studies have shown that administration of Repatha<sup>®</sup> to pregnant cynomolgus monkeys throughout gestation (at exposure levels12-times higher than patients receiving Repatha<sup>®</sup> at 420 mg QM) resulted in no effects on embryo-fetal/neonatal growth and development through to 6 months postpartum (Evolocumab Investigator's Brochure 2015). However, clinical data of Repatha<sup>®</sup> use in pregnancy is limited, therefore safety of Repatha<sup>®</sup> in pregnancy is considered to be missing information and this is reflected in the SmPC.

The SmPC states the following on use of Repatha® in association with pregnancy:

- There are no or limited amount of data from the use of Repatha<sup>®</sup> in pregnant women. Animal studies do not indicate direct or indirect effects with respect to reproductive toxicity.
- Repatha<sup>®</sup> should not be used during pregnancy unless the clinical condition of the woman requires treatment with evolocumab.

**Similarly, s**afety of Repatha<sup>®</sup> whilst breast-feeding is considered to be missing information. Published literature **indicates** that **in general**, there is a low risk of maternally-administered monoclonal antibodies resulting in pharmacologically relevant systemic exposures in breastfed infants, the milk-to-serum concentration ratio of IgGs being low (Kim et al, 1992; Telemo et al., 1996; Ostensen and Eigenmann, 2004; Mahadevan et al, 2005; Vasiliauskas et al, 2006). In studies of breast-feeding women treated with other therapeutic monoclonal antibodies, these antibodies were not present in breast milk at detectable concentrations (Vasiliauskas et al, 2006, Kane and Acquah, 2009). In addition, large molecules are known to have low oral bioavailability in the infant gastrointestinal tract (Van de Perre, 2003; Lobo et al, 2004; Hurley and Theil, 2011).

The SmPC states the following on use of Repatha® whilst breast-feeding:

- It is unknown whether evolocumab is excreted in human milk.
- A risk to breastfed newborns/infants cannot be excluded.

A decision must be made whether to discontinue breast-feeding or discontinue/abstain from Repatha<sup>®</sup> therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

#### 7.2 Rationale

In light of the limited data available on use of Repatha<sup>®</sup> in association with pregnancy and/or lactation, this study is being conducted in response to a request by the EMA to



provide data on outcomes of pregnancy in women (and their infants to the age of 12 months) exposed to Repatha<sup>®</sup> prior to or during pregnancy and/or breast-feeding.

In women of child-bearing age in Europe, South Africa and Australia those most likely to have been identified as requiring Repatha<sup>®</sup> for control of hypercholesterolaemia are those diagnosed with FH. Introduction of this particular pharmacological intervention in the majority of non-FH women is anticipated to occur beyond reproductive age.

Considering the low rate of FH diagnosis and the small number of Repatha<sup>®</sup>-exposed pregnancies anticipated to occur, routine pharmacovigilance surveillance based solely on spontaneous reporting is unlikely to provide the information required by the EMA, in the post-launch period. To address this, a separate study is required, with a targeted, proactive approach to identify cases and seek appropriate follow-up of outcomes of pregnancy in women with FH who have received Repatha<sup>®</sup> during pregnancy and/or breast-feeding.

This multinational observational study is expected to enrol female FH patients, identified in collaboration with specialist physicians and patient groups:

- Females with FH exposed to Repatha<sup>®</sup> during pregnancy and/or breast-feeding will form the exposed cohort, and
- Females with FH unexposed to Repatha<sup>®</sup> during pregnancy and breast-feeding will form the internal comparator group. Although no formal comparison of exposed/unexposed subjects is planned, capturing outcomes of pregnancy in a rare population unexposed to Repatha<sup>®</sup> will provide contemporary reference **data** against which to consider outcomes in exposed pregnancies.

#### 7.3 Statistical Inference (Estimation or Hypothesis)

No formal hypothesis will be tested in this study. Statistical analyses will be descriptive only. No statistical inference is planned.

#### 8. Research Question and Objectives

The purpose of the study is to evaluate outcomes of pregnancy in females diagnosed with FH, exposed to Repatha<sup>®</sup> during pregnancy. This includes follow-up of their infants to the age of 12 months.

#### 8.1 Primary Objective

To describe congenital anomalies in infants of females with FH exposed to Repatha<sup>®</sup> within 15 weeks prior to or during pregnancy, followed to the age of 12 months.



#### 8.2 Secondary Objectives

- To describe outcomes of pregnancy (other than congenital anomalies) in females with FH exposed to Repatha<sup>®</sup> within 15 weeks prior to or during pregnancy
- To describe outcomes of pregnancy in females with FH not exposed to Repatha<sup>®</sup> within 15 weeks prior to or during pregnancy
- To describe **health and developmental** outcomes in infants up to the age of 12 months, born to females diagnosed with FH and **unexposed or** exposed to Repatha<sup>®</sup> **during pregnancy and/or breastfeeding.**

#### 9. Research Methods

#### 9.1 Study Design

The study is a multinational (Europe, South Africa and Australia) prospective observational cohort study designed to capture data on outcomes of pregnancy in women diagnosed with FH. Within this population, the exposure of interest is administration of Repatha<sup>®</sup> during pregnancy and/or breast-feeding. The primary and secondary outcome measures are congenital anomaly and other outcomes of pregnancy **or infancy**, respectively.

To maximise the enrolment of eligible subjects this study will be conducted at sites which specialise in treatment of FH patients, and which are connected to local national and regional FH patient groups. All eligible patients at each study site will be invited to consent to be enrolled into the study; there is no limit to the number of subjects enrolled.

At the individual subject level, data of interest include demographics, medical and obstetric history at the time of confirmation of pregnancy within the study observation period. The subject will be followed **to determine** the outcome of pregnancy, including follow-up of the infant(s) to 12 months post-delivery. Data capture may be retrospective if a pregnancy occurring during the study period is detected after delivery.

Study site staff will abstract data from patient notes and entered into the sponsor's electronic database. There will be independent external expert adjudication of congenital anomaly to ensure consistency and accuracy of reporting. Analyses will be conducted by the sponsor.

This is a non-interventional, observational study and is not intended to alter the clinical management of patients.

#### 9.2 Setting and Study Population

#### 9.2.1 Study Period

Data will be captured for pregnancies occurring between June 2016 and June 2026.



#### 9.2.2 Selection and Number of Sites

Sites in Europe, South Africa and Australia where pregnant FH patients are treated will be considered suitable. These are anticipated to be national or regional FH referral centres, or other specialist sites which treat FH patients. Potential sites will be approached and selection confirmed according to Amgen Standard Operating Procedures (SOPs), based on interest in participation as a study site, willingness and ability to comply with the protocol and data entry conventions, and agreement to follow the subjects throughout the observation period.

**An estimated 50 to** 70 sites are expected to participate in the study. As many countries as possible within Europe, as well as South Africa and Australia, are invited and encouraged to participate. Site identification is expected to continue during the course of the study, to maximise the catchment across the FH population and hence the number of potential study subjects.

To maximise the number of subjects enrolled:

- A key criterion for selection of a study site is that the Investigator is a physician specialising in the treatment of FH.
- The Investigator will be aware of pregnancies in the regional or national FH population and will routinely advise women on management of their FH during pregnancy and breast-feeding.
- The Investigator and the sponsor will seek to proactively engage with national and local FH patient networks, to raise awareness of the study.
- Physicians may also be contacted if Repatha<sup>®</sup>-exposed pregnancies at their clinic are reported through Amgen's routine surveillance system; patient confidentiality will not be breached; the physician will be alerted to the pregnancy and will be encouraged to consider the patient's eligibility and invite them to consent to enrol in the study.
- There is no limit on the number of sites to be opened; as many sites as possible will be sought, in all participating countries, with no minimum on the number of eligible subjects expected to be enrolled at any site.

#### 9.2.3 Subject Eligibility

#### 9.2.3.1 Inclusion Criteria

- Females diagnosed with FH
- Confirmed pregnancy during the study observation period
  - Pregnancies identified retrospectively but within the study period will be included
  - Multiple pregnancies, occurring in the same woman within the study period, will all be included (as separate pregnancies)
- Provided informed consent to follow-up in this study, for subject and their infant(s) born during the study observation period



#### 9.2.3.2 Exclusion Criteria

There are no exclusion criteria

#### 9.2.4 Matching

Not applicable

#### 9.2.5 Baseline Period

The index date is the date of diagnosis of pregnancy. The baseline period covers subject history prior to the index date. Demographic factors and all relevant medical and clinical history at diagnosis of pregnancy will be reported as baseline subject status.

#### 9.2.6 Study Follow-up

Follow-up duration may differ for each individual subject, depending on the outcome of pregnancy: Initial baseline information will be recorded at confirmation of pregnancy and the subject will be followed for outcome of pregnancy **and**, **if breastfeeding following a live birth, until termination of breastfeeding**. Information on pregnancy outcome, and on infant health **and development up to** 12 months after delivery, will be captured.

#### 9.3 Outcomes - Variables

Information available for each subject on all variables will be reported by study site staff in the study-specific database held by the sponsor. The original data source will be patient (maternal – infant) records, from routine follow-up of subjects:

- Maternal Data:
  - Demographics:
    - Country of residence
    - Age (at start of pregnancy, categorized into  $\leq$  19, 20-24, 25-29, 30-34, 35-39, 40-44,  $\geq$  45 year age categories)
    - Education (highest level)
    - Occupation
    - Height and weight (to calculate body mass index, categorised into < 20, 20-24, 25-29, ≥ 30 kg/m<sup>2</sup> body mass index categories)
  - Current pregnancy history:
    - Date of last menstrual period
    - Estimated date of delivery
    - Number of fetuses
    - Treatment for infertility

CONFIDENTIAL

- Medical history:
  - FH diagnosis status and method of diagnosis
  - Presence of significant comorbid conditions (hypertension, diabetes mellitus, epilepsy, other)
  - o Family history of congenital disorders
- Obstetric history:
  - Number of previous pregnancies and outcome
  - Previous maternal pregnancy complications
  - Previous fetal/neonatal abnormalities
  - History of subfertility
- Medications (product, dose, dose dates) taken within 3 months prior to or during pregnancy (excluding medication routinely administered during labour/delivery) and/or breast-feeding
- Lipid levels (triglycerides, total cholesterol, LDL-C, HDL-C)
- Congenital anomaly including congenital abnormality or malformation as defined by European Surveillance of Congenital Anomalies (EUROCAT) (See Appendix E for full list)
- Complications of pregnancy:
  - Pre-eclampsia
  - Gestational diabetes
- Outcomes of pregnancy: (See Appendix F for further definition):
  - Live birth (with / without congenital anomaly)
  - Neonatal death (with / without congenital anomaly)
  - Stillbirth (with / without congenital anomaly)
  - Elective termination (with / without congenital anomaly)
  - Miscarriage (with / without congenital anomaly)
  - Spontaneous abortion
  - Ectopic pregnancy
  - Molar pregnancy
- Mode of delivery:
  - Normal vaginal delivery
  - Operative vaginal delivery
  - Vaginal breech delivery
  - Caesarean section
- Complications of delivery:
  - Abnormal Cord gas
  - Fetal heart rate abnormalities
  - Abnormal amniotic fluid

- Blood transfusion resulting from post-partum haemorrhage;
- Thromboembolism
- Infant Data:
  - Infant status at delivery:
    - Infant(s) sex
    - Gestational age
    - Birth weight
    - Apgar score
  - Infant outcomes until 12 months of age:
    - Weight growth
    - Developmental delay (not meeting the usual developmental milestones during the first 12 months of age)
    - Hospitalisations (total number of days hospitalised; number of hospitalisation episodes during the first 12 months)
    - Chronic medication (defined as medication prescribed for a period of 4 weeks or more)
    - Breastfeeding (date of start/stop, exclusive breastfeeding [Yes/No])
- Exposure Variables:
  - Exposure to Repatha<sup>®</sup> (duration of exposure, doses, dose dates) within 15 weeks prior to conception and/or during pregnancy and/or whilst breast-feeding. In adult subjects a single dose of Repatha<sup>®</sup> constitutes exposure. In infants, exposure may occur in utero and/or via breast milk, within 15 weeks following the date of Repatha<sup>®</sup> dosing in the mother.

#### 9.3.1 Exposure Assessment

Exposure to Repatha<sup>®</sup> in the 15 weeks (ie, 5 half-lives of Repatha<sup>®</sup>) prior to or during pregnancy or breast-feeding will be entered by site staff into study-specific electronic case report forms and will be reported descriptively by dose and dates of administration. Exposure will be counted in doses of Repatha<sup>®</sup>.

The study population comprises females in Europe, South Africa and Australia diagnosed with FH and who are either pregnant or breast-feeding during the study period, and who provide informed consent to participate in the study, if applicable according to local requirements. Their infants will also be followed to the age of 12 months, following consent by the mother (if applicable per local regulations).

(Note: The therapeutic strategy assigned to each patient enrolled in the study will not be specified within this study protocol. Instead, it will be decided according to



routine clinical practice, hence the decision for medicinal prescription will be clearly dissociated from the decision to include the patient in the study).

#### 9.3.2 Outcome Assessment

Outcome Measures:

- The primary outcome measure is congenital anomaly. Any incidence of congenital anomaly will be diagnosed and classified by the study site Investigator, or by the subject's treating physician (eg, an obstetrician, paediatrician, neonatologist) if this is not the Investigator, and reported on the study-specific eCRF. Supporting documentation will be requested to enable independent adjudication of the diagnosis, by an external expert not participating as a study investigator. Where supporting documentation is not held at the same clinic/hospital/institution as the study site, contracts will be executed to allow sharing of medical records, as necessary.
- Secondary outcome measures include:
  - Pregnancy outcomes (live birth(s), stillbirth, spontaneous loss, elective termination, ectopic pregnancy, complications of pregnancy (eg, pre-eclampsia, gestational diabetes)
  - Delivery outcomes (mode of delivery; complications including requirement for blood transfusion, thromboembolism, fetal distress, amniotic fluid abnormality)
  - Infant status at delivery: gender; gestational age; Apgar score; birth weight
  - Infant outcomes at 6 and 12 months post-delivery (including growth, hospitalisation, chronic medication)

The secondary outcome measures will be reported on the study-specific eCRF, from information entered into the subject's notes as part of routine follow-up. Where supporting documentation is not held at the same clinic/hospital/institution as the study site, contracts will be executed to allow sharing of medical records, as necessary.

Adverse outcomes requiring a clinical diagnosis of congenital anomaly will be subject to the same independent adjudication as the primary outcome.

#### 9.3.3 Covariate Assessment

Not applicable

#### 9.3.4 Validity and Reliability

Study variables stated in this protocol are objective, relevant to the question under study and are accepted as appropriate by regulatory authorities.

Reports of clinically significant outcomes will receive medical review.

Independent expert adjudication will be sought for any reports of congenital anomaly.



Reporting of exposure is expected to be accurate; subjects with a genetic condition (FH) are likely to be aware of treatments taken for that condition, especially around pregnancy and breast-feeding. The burden of reporting dosing dates is not excessive, as Repatha<sup>®</sup> is administered regularly, once every two weeks or once monthly.

#### 9.4 Data Sources

Data will be provided by study site staff, utilising subject medical notes to abstract information in order to complete electronic CRFs in the study-specific electronic database, which will be provided by the sponsor.

Medical notes will be patient records at the study site and are also expected to include records from maternity/obstetric units.

#### 9.5 Study Size

The study will collect data on all pregnancies and births in females diagnosed with FH and identified via the specialist centres/networks, where the patient consents to participate. Based on a conservative estimated FH prevalence of 1 in 500, and a national diagnosis rate varying between 70% and 1% (Nordestgaard 2013), the number of subjects identified for inclusion in this study is not expected to be large. The EMA guideline EMEA/CHMP/203927/2005 "GUIDELINE ON RISK ASSESSMENT OF MEDICINAL PRODUCTS ON HUMAN REPRODUCTION AND LACTATION: FROM DATA TO LABELLING" assumes an overall incidence of birth defects of 3% in order to derive the number of first trimester pregnancies exposed to a medicinal product that is needed to exclude a certain level of risk. The Guideline further states that if no increased incidence of malformations is observed within at least 300 first trimester-exposed, prospectively collected pregnancies with known pregnancy outcomes (births or fetopathological examinations) then the conclusion might be reached that the medicinal product is not responsible for a 10-fold or more increase of the overall incidence of malformations. In accordance with the Guideline, this study will endeavour to enrol 300 pregnancies exposed to Repatha in the first trimester in order to meet the primary objective of this study. The maximum number of unexposed pregnancies will be limited to a ratio of 2 unexposed to 1 exposed; ie, the maximum will be 600 unexposed pregnancies. In addition, the maximum of unexposed pregnancies originating from a single country will be limited to the minimum of N = 150 or tenfold the expected proportion of births out of the combined total of live births as reported by the relevant Bureaus of Statistics in the participating countries (Appendix H). For example, the observed number of live births in Norway in 2017



represented 1.5% of the births across all participating countries. Therefore, no more than N = 88 (10 x 1.5% = 15% of 600) unexposed pregnancies will originate from Norway. The observed number of United Kingdom births represents 19.6% of all 2017 live births across all countries; tenfold 19.6% of 600 would exceed the target of 600, therefore the number of unexposed pregnancies from the United Kingdom will be capped at N=150. This will ensure we enrol as many unexposed pregnancies as possible whilst avoiding that unexposed pregnancies will originate from a single country only.

#### 9.6 Data Management

Data are abstracted by site staff from subject notes into an electronic database provided by the sponsor. The sponsor provides protocol-specific training to all site staff delegated to abstract subject data. An eCRF Completion Guideline is provided.

The Amgen representative(s) and regulatory authority inspectors are responsible for contacting and visiting the Investigator for the purpose of inspecting the facilities and, upon request, inspecting the various records of the clinical study (eg, CRFs and other pertinent data) provided that subject confidentiality is respected.

The Clinical Monitor or designee is responsible for verifying the CRFs at regular intervals throughout the study to verify adherence to the protocol completeness, accuracy, and consistency of the data; and adherence to local regulations on the conduct of research. The Clinical Monitor, or designee is to have access to subject medical records and other study-related records needed to verify the entries on the CRFs in accordance with the local laws and regulations.

The Investigator agrees to cooperate with the Clinical Monitor, or designee to ensure that any problems detected in the course of these monitoring visits, including delays in completing CRFs, are resolved.

In accordance with the sponsor's audit plans, this study may be selected for audit by representatives from Amgen's Global Compliance Auditing function (or designees). Review of study-related records will occur to evaluate the study conduct and compliance with the protocol, and applicable regulatory requirements.



Data capture for this study is planned to be electronic:

- All source documentation supporting entries into the electronic CRFs must be maintained and available upon request.
- Updates to electronic CRFs will be automatically documented through the software's "audit trail".
- To ensure the quality of clinical data across all subjects and sites, a clinical data management review is performed on subject data received at Amgen. During this review, subject data is checked for consistency, omissions, and any apparent discrepancies. To resolve any questions arising from the clinical data management review process, data queries and/or site notifications are created in the EDC system database for site resolution and closed by Amgen reviewer.
- The Investigator signs only the Investigator Verification Form for this electronic data capture study. This signature indicates that the Investigator inspected or reviewed the data on the CRF, the data queries, and site notifications, and agrees with the content.

#### 9.6.1 Obtaining Data Files

Not applicable

#### 9.6.2 Linking Data Files

Not applicable

#### 9.6.3 Review and Verification of Data Quality

Automatic edit checks within the database and further manual review by the sponsor help to ensure quality and completeness of the data. Data queries are sent to site for clarification and resolution of discrepancies.

#### 9.7 Data Analysis

#### 9.7.1 Planned Analyses

#### 9.7.1.1 Interim Analyses

The appropriate regulatory authorities will receive:

- Interim reports of all analyses performed, to be submitted annually. (See Appendix G for **an example** Summary Table **template** to be included in the report)
- A feasibility report three years after study commencement, summarising the number of subjects enrolled, any exposure to Repatha<sup>®</sup> and describing primary and secondary outcome data.

#### 9.7.1.2 Primary Analysis

The primary analysis will be conducted at the end of the study observation period, which is currently scheduled to occur ten years after study commencement.



#### 9.7.2 Planned Method of Analysis

#### 9.7.2.1 General Considerations

Statistical analyses will be descriptive only. No statistical inference or imputations of missing data are planned.

Subject demographics and baseline characteristics will be summarised. Summary statistics for continuous variables will include the number of subjects, mean, median, standard deviation or standard error, minimum, and maximum. For categorical variables, the frequency and percentage will be reported.

Collection of study data may be both retrospective and/or prospective, depending on the time of enrolment of each study subject during the study observation period. Data obtained from retrospective and prospective subject identification will be reported separately.

Multiple pregnancies, occurring in the same woman within the study period, will be reported as separate pregnancies (with an addition of a relevant footnote in the respective tables, indicating that two or more pregnancies occurred in the same woman).

#### 9.7.2.2 Missing or Incomplete Data and Lost to Follow-up

For all study-related parameters, data are recorded as part of pregnancy follow-up in this cardiovascular high-risk population, and a high degree of completeness of follow-up and data recording can be expected. However, the necessity of obtaining data from multiple sources may incur an increased risk of being unable to obtain specific sets of patient notes. Proactive follow-up will also be encouraged.

There will be no imputation **of** missing data.

#### 9.7.2.3 Descriptive Analysis

## 9.7.2.3.1 Description of Study Enrolment

All eligible patients identified at each study site will be invited by the Investigators to provide informed consent to be enrolled into the study.

## 9.7.2.3.2 Description of Subject Characteristics

Subjects are women diagnosed with FH, treated at centres in Europe, South Africa and Australia, with pregnancy confirmed during the study observation period and who provide informed consent to participate in the study.



Exposed subjects are women who received Repatha<sup>®</sup> during pregnancy and/or breast-feeding; unexposed subjects are women who have not received Repatha<sup>®</sup> during pregnancy and/or breast-feeding. In infants, exposure may occur in utero and/or via breast milk, within 15 weeks following the date of Repatha<sup>®</sup> dosing in the mother.

#### 9.7.2.4 Analysis of the Primary and Secondary Endpoints

Analysis of Primary Objective:

Congenital anomalies will be summarised and descriptive statistics will be presented.

Congenital anomalies will be defined according to ICD10-BPA codes (codes included in Appendix E: EUROCAT Subgroups of Congenital Anomalies).

Analyses of Secondary Objectives:

Secondary objective outcome measures will be summarised and descriptive statistics will be presented.

Due to potentially insufficient data and consequent lack of statistical power, it is unlikely that comparisons between the 2 groups will provide meaningful results, hence, no formal comparison of exposed/unexposed subjects is planned.

#### 9.7.2.5 Sensitivity Analysis

None planned

9.7.2.6 Subgroup Analysis

None planned

#### 9.7.2.7 Stratified Analysis

For the secondary objective of describing health and developmental outcomes in infants up to 12 months of age, analyses will be stratified according to whether the infant was exposed to Repatha<sup>®</sup> (in the 15 weeks prior to conception or in the first trimester of pregnancy, in the second or third trimester of pregnancy, and/or whilst breast-feeding). In addition, a stratified analysis will be conducted by exposure to other lipid modifying therapies (including statins, PCSK9 inhibitors, CETP inhibitors, and others).

In addition, data obtained from retrospective and prospective subject identification will be reported separately (to account for the possibility that subjects enrolled retrospectively may differ from those enrolled prospectively).



Results from mothers are to be presented using the following columns: (i) 'unexposed', (ii) 'exposed but stopped prior to conception', (iii) 'exposure in 1<sup>st</sup> trimester (up to 15 weeks)', (iv) 'exposure in 2<sup>nd</sup>/3<sup>rd</sup> trimesters', (v) 'exposed at conception and during 1<sup>st</sup> trimester but stopped during 2<sup>nd</sup>/3<sup>rd</sup> trimesters, (vi) 'exposed throughout pregnancy', (vii) 'exposure during breastfeeding only', and (viii) 'exposure anytime during pregnancy and up to 15 weeks, and breastfeeding'. Columns will not be mutually exclusive.

# **9.7.2.7.1** Sensitivity Analysis for Residual Confounding and Bias Not applicable

#### 9.7.2.7.2 Other Sensitivity Analysis

None planned

#### 9.7.3 Analysis of Safety Endpoint(s)/Outcome(s)

Apart from the primary and secondary analyses, no other Safety analyses are planned as part of this study.

#### 9.8 Quality Control

Source data verification will be performed at the study site, in accordance with Amgen SOPs.

The Investigator is to maintain a list of appropriately qualified persons to whom he/she has delegated study duties. All persons authorized to make entries and/or corrections on CRFs will be included on the Amgen Delegation of Authority Form.

Source documents are original documents, data, and records from which the subject's CRF data are obtained. These include but are not limited to hospital records, clinical and office charts, laboratory and pharmacy records, diaries, microfiches, radiographs, and correspondence.

The Investigator and study staff are responsible for maintaining a comprehensive and centralized filing system of all study-related (essential) documentation, suitable for inspection at any time by representatives from Amgen and/or applicable regulatory authorities.



Elements to include:

- Subject files containing completed CRF, informed consent forms, as applicable, and subject identification list
- Study files containing the protocol with all amendments, copies of pre-study documentation, and all correspondence to and from the IRB/IEC or other relevant ethical review board and Amgen

In addition, all original source documents supporting entries in the CRFs must be maintained and be readily available.

Retention of study documents will be governed by the contractual agreement with Amgen.

Amgen retains all data, programs and outputs generated for the study. At study close, data are uploaded from the Medidata Rave database and stored in accordance with Amgen SOPs. Statistical programming and outputs are locked in the analysis environment and no updates are permitted; standard statistical programming processes will be followed.

### 9.9 Limitations of the Research Methods

#### 9.9.1 Information Bias

Information bias may occur from participants who are recruited retrospectively more likely to have adverse outcomes. This will occur because participants with adverse outcomes will make the clinician consider recruiting them.

#### 9.9.2 Selection Bias

The intention is to enrol as many eligible subjects as possible, with no limit on numbers at site or country level. The inclusion criteria are not restrictive, and all eligible FH women identified will be invited to enrol into the study.

Selection bias may occur due to pregnant women without adverse outcomes potentially being less likely to be told about the study, or less inclined to participate in the study. To help to minimise selection bias arising from preferential enrolment of subjects experiencing adverse outcomes rather than those with normal outcomes, sites will be requested to enrol all eligible patients whether retrospectively or prospectively identified, and regardless of outcomes which are already known.

To account for the possibility that subjects enrolled retrospectively may differ from those enrolled prospectively, data obtained from retrospective and prospective subject identification will be reported separately.



Study sites will be asked to record, annually for the duration of the study, the number of pregnant FH women attending their clinic, and the number who are eligible but do not consent to enrol into the study. Comparing these numbers with the number of enrolled subjects will help to assess case ascertainment.

## 9.9.3 Limitations due to Missing Data and/or Incomplete Data Although the necessity of obtaining data from multiple sources may incur an increased risk of being unable to obtain specific sets of patient notes,

**m**issing/incomplete data is unlikely to be a limitation for subjects identified and enrolled into this study, as physicians treating FH women pay particular attention to their clinical management during pregnancy and breast-feeding. It is not expected that information on outcomes will be missing, due to the critical nature of follow-up of pregnant women and their infants regardless of an adverse or a normal outcome. Additionally, Amgen will review all study data thoroughly and will follow up directly with study sites to query for missing information.

#### 9.10 Other Aspects

The sites chosen to participate in this study are regional or national referral centres, with links to other FH specialists; in collaboration with these sites, and with FH patient networks and associations, Amgen will raise and proactively maintain awareness of the study to maximize the number of cases detected.

## 10. Protection of Human Subjects

#### 10.1 Informed Consent

An initial sample informed consent form is provided for the Investigator to prepare the informed consent document to be used at his or her site, **according to local regulations**. Updates to the template are to be communicated formally in writing from the Amgen Clinical Study Manager to the Investigator. The written informed consent document is to be prepared in the language(s) of the potential subject population.

Before a subject's participation in the study, the Investigator is responsible for obtaining written informed consent, where applicable by local regulations, from the subject or legally acceptable representative after adequate explanation of the aims, methods, anticipated benefits, and potential hazards of the study and before any protocol-specific activities/assessments are conducted. A legally acceptable representative is an individual or other body authorized under applicable law to consent, on behalf of a prospective subject/patient, to the subject's/patient's participation in the study.



The acquisition of informed consent and the subject's/patient's agreement or refusal of his/her notification of the primary care physician is to be documented in the subject's medical records, and the informed consent form is to be signed and personally dated by the subject or a legally acceptable representative and by the person who conducted the informed consent discussion. The original signed informed consent form is to be retained in accordance with institutional policy, and a copy of the signed consent form is to be provided to the subject or legally acceptable representative.

If a potential subject is illiterate or visually impaired and does not have a legally acceptable representative, the Investigator must provide an impartial witness to read the informed consent form to the subject and must allow for questions. Thereafter, both the subject and the witness must sign the informed consent form to attest that informed consent was freely given and understood.

In addition to the above, each study site must follow all locally applicable regulations and requirements for obtaining parental/legally acceptable representative consent for follow-up of infants born to study subjects.

## 10.2 Institutional Review Board (IRB)/Independent Ethics Committee (IEC)

A copy of the protocol, proposed informed consent form, as applicable, other written subject/patient information, and any proposed advertising material must be submitted to the IRB/IEC or other relevant ethical review board for written approval. A copy of the written approval of the protocol, and informed consent form, as applicable must be received by Amgen before the study can be executed.

The Investigator must submit and, where necessary, obtain approval from the IRB/IEC or other relevant ethical review board for all subsequent protocol amendments and changes to the informed consent document, as applicable. The Investigator is to notify the IRB/IEC or other relevant ethical review board of deviations from the protocol or serious adverse event(s) occurring at the site and other adverse event reports received from Amgen, in accordance with local procedures.

The Investigator is responsible for obtaining annual IRB/IEC or other relevant ethical review board approval /renewal throughout the duration of the study. Copies of the Investigator's reports, where applicable by local regulations and the IRB/IEC or other relevant ethical review board continuance of approval must be sent to Amgen.



#### 10.3 Subject Confidentiality

The Investigator must ensure that the subject's confidentiality is maintained for documents submitted to Amgen.

- Subjects are to be identified by a unique subject identification number.
- Where permitted, date of birth is to be documented and formatted in accordance with local laws and regulations.
- On the CRFs demographics page, in addition to the unique subject identification number, include the age at time of enrolment.
- Documents that are not for submission to Amgen (eg, signed informed consent forms, as applicable) are to be kept in confidence by the Investigator, except as described below.

In compliance with Local country regulations/ICH GCP Guidelines, it is required that the Investigator and institution permit authorized representatives of the company, of the regulatory agency(s), and the IRB/IEC or other relevant ethical review board direct access to review the subject's original medical records for verification of study-related activities and data. Direct access includes examining, analyzing, verifying, and reproducing any records and reports that are important to the evaluation of the study. The Investigator is obligated to inform and obtain the consent of the subject to permit such individuals to have access to his/her study-related records, including personal information.

#### 11. Collection of Safety Information and Product Complaints

In this study, Safety reporting is required only for subjects exposed to Repatha®

For subjects known to be exposed to Repatha<sup>®</sup> within the 15 weeks prior to or during pregnancy and/or during breastfeeding, a Pregnancy Notification Worksheet and/or Lactation Notification Worksheet (Appendix I), as appropriate, is to be submitted to Amgen and will be collected until termination of breastfeeding, otherwise until **12 months post-partum**.

#### 11.1 Definition of Safety Events

#### 11.1.1 Adverse Events

An adverse event is any untoward medical occurrence in a subject/patient administered a pharmaceutical product(s) irrespective of a causal relationship with this treatment.

An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated



with the use of a medicinal product(s), combination product or medical device whether or not considered related to the product(s). The definition of an adverse event includes:

- Worsening of a pre-existing condition or underlying disease
- Events associated with the discontinuation of the use of a product(s), (eg, appearance of new symptoms)

It is the investigator's responsibility to evaluate whether an adverse event is related to an Amgen product prior to reporting the adverse event to Amgen. Regardless of causality, for this study all adverse events (non-serious, serious, related and non-related) experienced by subjects exposed to Repatha<sup>®</sup> should be reported to Amgen.

An adverse device effect is any adverse event related to the use of a medical device. Adverse device effects include adverse events resulting from insufficient or inadequate instructions for use, adverse events resulting from any malfunction of the device, or adverse events resulting from use error or from intentional misuse of the device.

#### 11.1.2 Serious Adverse Events

A serious adverse event is any adverse event as defined above that meets at least one of the following serious criteria:

- is fatal
- is life threatening (places the subject at immediate risk of death)
- requires in-patient hospitalization or prolongation of existing hospitalization
- results in persistent or significant disability/incapacity
- is a congenital anomaly/birth defect
- is an "other significant medical hazard" that does not meet any of the above criteria

A hospitalization meeting the regulatory definition for "serious" is any in-patient hospital admission that includes a minimum of an overnight stay in a healthcare facility.

"Other significant medical hazards" refer to important medical events that may not be immediately life-threatening or result in death or hospitalization, but may jeopardize the subject or may require intervention to prevent one of the other outcomes listed in the definition above. Examples of such events could include allergic bronchospasm, convulsions, and blood dyscrasias, drug-induced liver injury, events that necessitate an emergency room visit, outpatient surgery, or other events that require other urgent intervention.



#### 11.1.3 Other Safety Findings

Other Safety Findings (regardless of association with an adverse event) include:

- Medication errors, overdose, whether accidental or intentional, misuse, or abuse, involving an Amgen product,
- Pregnancy and lactation exposure,
- Transmission of infectious agents,
- Reports of uses outside the terms for authorized use of the product including off-label use,
- Occupational exposure,
- Any lack or loss of intended effect of the product(s).

#### 11.1.4 Product Complaints

Product Complaints include any written, electronic or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or performance of a product or device after it is released for distribution to market or clinic by either Amgen or by distributors and partners for whom Amgen manufactures the material. This includes any drug(s) or device(s) provisioned and/or repackaged /modified by Amgen. Drug(s) or device(s) includes investigational product.

#### 11.2 Safety Reporting Requirements

The Investigator is responsible for ensuring that safety events (adverse events, product complaints and other safety findings) observed by the Investigator or reported by the subject that occur during the **study** observation period are recorded in the subject's appropriate study documentation. The observation period for this study consists of 2 distinct periods: 1) the retrospective observation period that is defined as the time between diagnosis of pregnancy and the subject's enrolment into the study and, 2) the prospective observation period defined as the time between subject's enrolment date until the end of her and the infant's follow-up.

For safety events that occurred in the retrospective observation period, the date on which the investigator accessed the subject's medical charts to abstract the relevant retrospective information should be entered into the field "Date Investigator became aware of this Event" on the Event eCRF. Safety events identified in both the retrospective and prospective period must be submitted as individual case safety reports to Amgen via the applicable Amgen Safety Reporting Form (paper or electronic form) within 1 business day of Investigator awareness. Non-serious adverse events must be reported in an expeditious manner, not to exceed 15 calendars days of investigator awareness.

CONFIDENTIAL

If the electronic data capture (EDC) system is unavailable to the site staff to report the adverse event, the information is to be reported to Amgen via a paper Electronic Adverse Event Contingency Report Form within 1 business day of the Investigator's awareness. For EDC studies where the first notification of an Adverse Event is reported to Amgen via the Electronic Adverse Event Contingency Report Form, the data must be entered into the EDC system when the system is again available.

See Appendix C for sample Electronic Adverse Event Contingency Report Form, Appendix D for Additional Safety Reporting Information regarding the adverse event grading scale used in this study.

The Investigator may be asked to provide additional information for any event submitted, which may include a discharge summary or extracts from the medical record. Information provided about the event must be consistent with information recorded on study Case Report Forms (CRFs) where safety data may also be recorded (eg, Event CRF).

## 11.2.1 Safety Reporting Requirement to Regulatory Bodies

Amgen will report safety data as required to regulatory authorities, Investigators/institutions, IRBs/IECs or other relevant ethical review board(s) in accordance with Pharmacovigilance guidelines and in compliance with local regulations. The Investigator is to notify the appropriate IRB/IEC or other relevant ethical review board of Serious Adverse Events in accordance with local procedures and statutes.

Adverse reactions that are suspected to be related to medicinal products other than Repatha<sup>®</sup> should be notified by the Investigator to the competent authority in the Member State where the reactions occurred or to the marketing authorisation holder of the suspected medicinal product in accordance with local reporting requirements.

## 12. Administrative and Legal Obligations

## 12.1 Protocol Amendments and Study Termination

Amgen may amend the protocol at any time. If Amgen amends the protocol, written agreement from the Investigator must be obtained where applicable per local governing law and/or regulations. The IRB/IEC or other relevant ethical review board must be informed of all amendments and give approval. The Investigator must send a copy of the approval letter from the IRB/IEC or other relevant ethical review board to Amgen.

Amgen reserves the right to terminate the study at any time. Both Amgen and the Investigator reserve the right to terminate the Investigator's participation in the study



according to the contractual agreement. The Investigator is to notify the IRB/IEC or other relevant ethical review board in writing of the study's completion or early termination and send a copy of the notification to Amgen.

## 13. Plans for Disseminating and Communicating Study Results

The intent is to publish the results from this study. Publication may be in the form of Congress abstracts or posters, and/or manuscript(s).

## 13.1 Publication Policy

Authorship of any publications resulting from this study will be determined on the basis of the International Committee of Medical Journal Editors (ICJME) Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals, which states:

- Authorship credit should be based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; (3) final approval of the version to be published and (4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Authors should meet conditions 1, 2, and 3 and 4.
- When a large, multicenter group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship defined above.
- Acquisition of funding, collection of data, or general supervision of the research group, alone, does not justify authorship.
- All persons designated as authors should qualify for authorship, and all those who qualify should be listed.
- Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.

All publications (eg, manuscripts, abstracts, oral/slide presentations, book chapters) based on this study must be submitted to Amgen for corporate review. The vendor agreement will detail the procedures for, and timing of, Amgen's review of publications.

## 14. References

Bartels A, O'Donoghue K. Cholesterol in pregnancy: a review of knowns and unknowns. Obstetric Medicine 2011; 4:147-151.

Brown MS, Goldstein JL. Biomedicine. Lowering LDL--not only how low, but how long? Science. 2006; 311:1721-1723.

Connor W, Cerquera M, Connor R, et al. The plasma lipids, lipoproteins, and diet of the Tarahumara Indians of Mexico. Amer J Clin Nutr. 1978:31:1131-1142.

DeSesso JM, Williams AL, Ahuja A, Bowman CJ, Hurtt ME (2012) The placental transfer of immunoglobulins, and safety assessment of biopharmaceuticals in pregnancy. Crit Rev Toxicol 42:185-210

Dietschy J, Turley S, Spady D. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res. 1993; 34:1637-1659

EMEA/CHMP Guideline on the Exposure to Medicinal Products During Pregnancy, EMEA/CHMP/313666/2005

Evolocumab Investigator's Brochure, Edition 9, September 2015

Homanics G, Smith T, Zhang S, et al. Targeted modification of the apolipoprotein B gene results in hypobetalipoproteinemia and developmental abnormalities in mice. Proc Natl Acad Sci 1993; 90:2389-2393.

Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci. 2007; 32:71-77.

Hurley W, Theil P. Perspectives on immunoglobulins in colostrum and milk. Nutrients. 2011; 3:442-474.

International Conference on Harmonisation (ICH). 2009. Tripartite Guideline M3 (R2) Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals.

Kane S and Acquah L. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol. 2009; 104(1):228-33.

Kim K, Keller M, Heiner D. Immunoglobulin G subclasses in human colostrum, milk and saliva. Acta Paediatr. 1992; 81:113-118.

Lobo E, Hansen R, Balthasar J. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004; 93:2645-2668.

Mahadevan U, Kane S, Sandborn W, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2005; 21:733-738.

McMurry M, Connor W, Goplerud C. The effects of dietary cholesterol upon the hypercholesterolemia of pregnancy. Metabolism. 1981; 30:869-879.

Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J. 2008; 29:2625-2633



Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, et al. (2013) Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. European Heart Journal, 34(45):3478-90

Ostensen M, Eigenmann GO. Etanercept in breast milk. J Rheumatol. 2004; 31:1017-1018.

Rader D, Cohen J, Hobbs H. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest. 2003; 111:1795-1803.

Repatha<sup>®</sup> EPAR; ema.europa.eu/docs/en\_GB/document\_library/EPAR\_-Summary\_for\_the\_public/human/003766/WC500191401.pdf

Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. *Proc Natl Acad Sci USA*. 2003;100:928-933.

Telemo E, Hanson LA. Antibodies in milk. J Mammary Gland Biol Neoplasia. 1996; 1:243-249

Van de Perre P. Transfer of antibody via mother's milk. Vaccine. 2003; 21:3374-3376

Vasiliauskas E, Church J, Silverman N, Barry M, Targan S, et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol. 2006; 4:1255-1258.

WHO ICD10 International Statistical Classification of Diseases and Related Health Problems Tenth Revision Volume 2 Second Edition

Woollett LA. Maternal cholesterol in fetal development: transport of cholesterol from the maternal to the fetal circulation. *Am J Clin Nutr.* 2005;82:1155-1161.

15. Appendices



Appendix A. List of Stand-alone Documents

None



#### Appendix B. ENCePP Checklist for Study Protocols

#### Study title:

A Multinational Observational Study to Evaluate the Safety of Repatha® in Pregnancy

Study reference number: 20150162				
Section 1: Milestones	Yes	No	N/A	Page Number(s)
1.1 Does the protocol specify timelines for				
1.1.1 Start of data collection <sup>1</sup>	$\bowtie$			Sctn 6
1.1.2 End of data collection <sup>2</sup>	$\bowtie$			Sctn 6
1.1.3 Study progress report(s)	$\bowtie$			Sctn 6
1.1.4 Interim progress report(s)	$\bowtie$			Sctn 6
1.1.5 Registration in the EU PAS register	$\bowtie$			Sctn 6
1.1.6 Final report of study results.	$\bowtie$			Sctn 6

Comments:

<sup>1</sup> Date from which information on the first study is first recorded in the study dataset or, in the case of secondary use of data, the date from which data extraction starts.

<sup>2</sup> Date from which the analytical dataset is completely available.

Section 2: Research question	Yes	No	N/A	Page Number(s)
2.1 Does the formulation of the research question and objectives clearly explain:				
2.1.1 Why the study is conducted? (e.g. to address an important public health concern, a risk identified in the risk management plan, an emerging safety issue)				Sctn 7.2
2.1.2 The objective(s) of the study?	$\square$			Sctn 8.1/2
2.1.3 The target population? (i.e. population or subgroup to whom the study results are intended to be generalised)				Sctn 8
2.1.4 Which formal hypothesis(-es) is (are) to be tested?				
2.1.5 If applicable, that there is no <i>a priori</i> hypothesis?				

Comments:

This is a descriptive study with no formal hypothesis N/A Section 3: Study design Yes No Page Number(s) 3.1 Is the study design described? (e.g. cohort, case-control,  $\ge$ Sctn 9.1 randomised controlled trial, new or alternative design) 3.2 Does the protocol specify the primary and secondary  $\boxtimes$ Sctn 9.2.2 (if applicable) endpoint(s) to be investigated? 3.3 Does the protocol describe the measure(s) of effect? (e.g. relative risk, odds ratio, deaths per 1000 person-years,  $\boxtimes$ absolute risk, excess risk, incidence rate ratio, hazard ratio, number needed to harm (NNH) per year) Comments:

The number of exposed cases is expected to be very small; analyses are descriptive only

Section 4: Source and study populations	Yes	No	N/A	Page Number(s)		
4.1 Is the source population described?	$\bowtie$			Sctn 9.1.2		
<ul> <li>4.2 Is the planned study population defined in terms of:</li> <li>4.2.1 Study time period?</li> <li>4.2.2 Age and sex?</li> <li>4.2.3 Country of origin?</li> <li>4.2.4 Disease/indication?</li> <li>4.2.5 Co-morbidity?</li> <li>4.2.6 Seasonality?</li> </ul>				Sctn 9.1.1 Sctn 9.1.3 Sctn 9.1.2 Sctn 9.1.3		
4.3 Does the protocol define how the study population will be sampled from the source population? (e.g. event or inclusion/exclusion criteria)				Sctn 9.1		
Comments:						
There are no co-morbidities or seasonality under study						
Section 5: Exposure definition and measurement	Yes	No	N/A	Page Number(s)		
5.1 Does the protocol describe how exposure is defined and measured? (e.g. operational details for defining and categorising exposure)				Sctn 9.2.1		
5.2 Does the protocol discuss the validity of exposure measurement? (e.g. precision, accuracy, prospective						
ascertainment, exposure information recorded before the outcome occurred, use of validation sub-study)				Sctn 9.2.4		
5.3 Is exposure classified according to time windows? (e.g. current user, former user, non-use)				Sctn 9.6.3		
5.4 Is exposure classified based on biological mechanism of action and taking into account the pharmacokinetics and pharmacodynamics of the drug?				Sctn 9.2.1		
5.5 Does the protocol specify whether a dose-dependent or duration-dependent response is measured?				Sctn 9.2.1		
Comments: Exposure is classified as beginning at 15 weeks prior to co						

Exposure is classified as beginning at 15 weeks prior to conception (5 halflives of Repatha), and a single dose of Repatha at any time during pregnancy or breastfeeding is classified as exposure

Section 6: Endpoint definition and measurement	Yes	No	N/A	Page Number(s)
6.1 Does the protocol describe how the endpoints are defined and measured?	$\boxtimes$			Sctn 9.2.2
6.2 Does the protocol discuss the validity of endpoint measurement? (e.g. precision, accuracy, sensitivity, specificity, positive predictive value, prospective or retrospective ascertainment, use of validation sub-study)	$\boxtimes$			Sctn 9.2.2

Comments:

Endpoints will be reported verbatim, coded in ICD10-BPA according to Eurocat classification and independently adjudicated where congenital anomaly is the outcome

Section 7: Confounders and effect modifiers	Yes	No	N/A	Page Number(s)
7.1 Does the protocol address known confounders? (e.g. collection of data on known confounders, methods of controlling for known confounders)				
7.2 Does the protocol address known effect modifiers? (e.g. collection of data on known effect modifiers, anticipated direction of effect)				

#### Comments:

Confounding is not applicable for this study				
Section 8: Data sources	Yes	No	N/A	Page Number(s)
8.1 Does the protocol describe the data source(s) used in the study for the ascertainment of:				
8.1.1 Exposure? (e.g. pharmacy dispensing, general practice prescribing, claims data, self-report, face-to-face interview, etc.)				9.6.2
8.1.2 Endpoints? (e.g. clinical records, laboratory markers or values, claims data, self-report, patient interview including scales and questionnaires, vital statistics, etc.)				9.6.2
8.1.3 Covariates?	$\bowtie$			9.6.2
8.2 Does the protocol describe the information available from the data source(s) on:				
8.2.1 Exposure? (e.g. date of dispensing, drug quantity, dose, number of days of supply prescription, daily dosage, prescriber)				Sctn 9.1/6
8.2.2 Endpoints? (e.g. date of occurrence, multiple event, severity measures related to event)	$\boxtimes$			Sctn 9.1/6
8.2.3 Covariates? (e.g. age, sex, clinical and drug use history, co-morbidity, co-medications, life style, etc.)	$\boxtimes$			Sctn 9.2
8.3 Is a coding system described for:				
8.3.1 Diseases? (e.g. International Classification of Diseases (ICD)-10)				Appendix C
8.3.2 Endpoints? (e.g. Medical Dictionary for Regulatory Activities (MedDRA) for adverse events)	$\bowtie$			Appendix C
8.3.3 Exposure? (e.g. WHO Drug Dictionary, Anatomical Therapeutic Chemical (ATC)Classification System)				
8.4 Is the linkage method between data sources described? (e.g. based on a unique identifier or other)			$\boxtimes$	

#### Comments:

Exposure coding is not applicable as Repatha (band name) is the only exposure. Baseline covariates and exposure to concomitant medications other than Repatha throughout the observation period will be reported descriptively; it is not anticipated that analyses by covariate subgroups will be performed. No linkage will be performed.

Section 9: Study size and power	Yes	No	N/A	Page Number(s)
9.1 Is sample size and/or statistical power calculated?			$\boxtimes$	
· · · · · · · · · · · · · · · · · · ·				

#### Comments:

This is a signal detection study and is not powered for statistical significance



## Product: Evolocumab Protocol Number: 20150162 Date: 18 December 2018

Section 10: Analysis plan	Yes	No	N/A	Page Number(s)
10.1 Does the plan include measurement of excess risks?				
10.2 Is the choice of statistical techniques described?	$\boxtimes$			Sctn 9.6.2
10.3 Are descriptive analyses included?	$\square$			Sctn 9.6.2
10.4 Are stratified analyses included?	$\bowtie$			Sctn 9.6.3
10.5 Does the plan describe methods for adjusting for confounding?				
10.6 Does the plan describe methods addressing effect modification?			$\boxtimes$	
Comments:				
Descriptive analyses only; confounding is not applicable				
Section 11: Data management and quality control	Yes	No	N/A	Page Number(s)
Section 11: Data management and guality control           11.1 Is information provided on the management of missing data?	Yes	No	N/A	
11.1 Is information provided on the management of		No	N/A	Number(s)
<ul> <li>11.1 Is information provided on the management of missing data?</li> <li>11.2 Does the protocol provide information on data storage? (e.g. software and IT environment, database</li> </ul>		No	N/A	Number(s) Sctn 9.8.2
<ul> <li>11.1 Is information provided on the management of missing data?</li> <li>11.2 Does the protocol provide information on data storage? (e.g. software and IT environment, database maintenance and anti-fraud protection, archiving)</li> </ul>			N/A	Number(s) Sctn 9.8.2 Sctn 9.7
<ul> <li>11.1 Is information provided on the management of missing data?</li> <li>11.2 Does the protocol provide information on data storage? (e.g. software and IT environment, database maintenance and anti-fraud protection, archiving)</li> <li>11.3 Are methods of quality assurance described?</li> <li>11.4 Does the protocol describe possible quality issues</li> </ul>			N/A	Number(s) Sctn 9.8.2 Sctn 9.7 Sctn 9.5
<ul> <li>11.1 Is information provided on the management of missing data?</li> <li>11.2 Does the protocol provide information on data storage? (e.g. software and Π environment, database maintenance and anti-fraud protection, archiving)</li> <li>11.3 Are methods of quality assurance described?</li> <li>11.4 Does the protocol describe possible quality issues related to the data source(s)?</li> <li>11.5 Is there a system in place for independent review</li> </ul>				Number(s) Sctn 9.8.2 Sctn 9.7 Sctn 9.5 Sctn 9.7
<ul> <li>11.1 Is information provided on the management of missing data?</li> <li>11.2 Does the protocol provide information on data storage? (e.g. software and IT environment, database maintenance and anti-fraud protection, archiving)</li> <li>11.3 Are methods of quality assurance described?</li> <li>11.4 Does the protocol describe possible quality issues related to the data source(s)?</li> <li>11.5 Is there a system in place for independent review of study results?</li> </ul>				Number(s)Sctn 9.8.2Sctn 9.7Sctn 9.5Sctn 9.7

			Number(s)
12.1 Does the protocol discuss:			
12.1.1 Selection biases?	$\bowtie$		Sctn 9.8.1
12.1.2 Information biases?			
(e.g. anticipated direction and magnitude of such biases, validation sub-study, use of validation and external data, analytical methods)	$\boxtimes$		Sctn 9.8.1
12.2 Does the protocol discuss study feasibility? (e.g. sample size, anticipated exposure, duration of follow-up in a cohort study, patient recruitment)	$\boxtimes$		Sctn 9.6.1
12.3 Does the protocol address other limitations?	$\boxtimes$		Sctn 9.8.2
Comments:			
A report on study feasibility is planned at 3 years post-init	iation.		



Section 13: Ethical issues	Yes	No	N/A	Page Number(s)
13.1 Have requirements of Ethics Committee/Institutional Review Board approval been described?				Sctn10.1/2
13.2 Has any outcome of an ethical review procedure been addressed?				
13.3 Have data protection requirements been described?	$\bowtie$			Sctn 10.3

Comments:

No ethical review has yet taken place

Section 14: Amendments and deviations	Yes	No	N/A	Page Number(s)
14.1 Does the protocol include a section to document future amendments and deviations?	$\boxtimes$			Sctn 5

Comments:

Section 15: Plans for communication of study results	Yes	No	N/A	Page Number(s)
15.1 Are plans described for communicating study results (e.g. to regulatory authorities)?	$\boxtimes$			Sctn 9.6.1
15.2 Are plans described for disseminating study results externally, including publication?	$\boxtimes$			Sctn 13

PD

$\sim$	0.0	-	$\sim$		
- U	OT.	ш	ne	ווזי	S
<u> </u>	~.				· · ·

Name of the main author of the protocol:

Date: 9/11/2015

Signature: \_



## Appendix C. Sample Electronic Adverse Event Contingency Report Form

Chuc	AMGEN	60		Electronic Adverse Event Contingency Report Form													
	dy # 201501 ha≋ (evolocu					Fo	r Re	strict	ed Us	e							
		1114407				_				_							
Dessen		. <b>Al</b> ai a															
	for reporting																
□ Is not available due to internet outage at my site																	
□ Is not yet available for this study																	
□ Has been closed for this study																	
			DM/Sti	udy manager/.	Author prior	to pro	vidir	ig to s	ites:	SELL	ECT	OR	ТΥ	ΈE	IN.	A FAX#	\$>
	IFORMATION																
Site Nun	nber			Investigator								Country					
	Re	eporter			Phone Number					Fax	lumbe	er 、					
					( )					(		)					
2. SUBJE	CT INFORMA						1-					1.10					
	Subject ID Number			Age at event onset			Sex Race If applicable, provide End of a date						le End of S	tudy			
								]F □N	1								
If this is a f	If this is a follow-up to an event reported in the EDC system (eg, Rave), provide the adverse event term:																
				-	(eg, Rave), prov	ide the a	advers	eevent	term:								_
and start da				-	(eg, Rave), prov	ide the a	advers	eevent	term:								_
and start da 3. ADVER Provide the	ate: Day P RSE EVENT e date the Investig	Month	Ye	-		Month_	advers	ar	_								
and start da 3. ADVER Provide the Adverse	ate: Day P RSE EVENT e date the Investig Event <u>diagnosis</u> o	Month	ecame a	ware of this inform		Month_ Check	Ye	ar If serious				onship	that	t the F		Outcome	Check only if event is
and start da 3. ADVER Provide the Adverse If diagnosis is	ate: Day N <b>RSE EVENT</b> a date the Investig Event <u>diagnosis</u> of s unknown, enter si liagnosis, when kn	Month gator be r syndroi igns / syn	ecame a me mptoms	ware of this inform	nation: Day	Month_ Check only if event	Ye	ar If serious enter Serious	Is there a	reason may ha	able po ve be	ossibility en caus	ed b	v	vent	of Event	ifeventis related to study
and start da 3. ADVER Provide the Adverse If diagnosis is and provide d	ate: Day P <b>SE EVENT</b> <b>date the Investig</b> Event <u>diagnosis</u> of s unknown, enter s liagnosis, when kn up report	Month gator be r syndroi igns / syn own, in a	ecame a me mptoms a follow-	ware of this inform		Month Check only if event occurred before	Ye	ar If serious enter Serious Criteria	Is there a	neason may ha rug un d	able po ve beo erstuo	ossibility en caus dy or an	ed b Amg	y gen d	Event evice	of Event Resolved	if event is related to
and start da 3. ADVER Provide the Adverse If diagnosis is and provide d <i>List one ever</i>	ate: Day N <b>RSE EVENT</b> a date the Investig Event <u>diagnosis</u> of s unknown, enter si liagnosis, when kn	Month gator be r syndroi igns / syn own, in a s fatal, en	ecame a me mptoms a follow-	ware of this inform	nation: Day	Month_ Check only if event occurred	Ye	ar If serious enter Serious Criteria code (see	Is there a	neason may ha rug un d	able po ve beo erstuo	ossibility en caus dy or an	ed b Amg	y gen d	Event evice	of Event Resolved	ifeventis related to study procedure eg,
and start da 3. ADVER Provide the Adverse If diagnosis is and provide d List one even cause of eeat	ate: Day I RSE EVENT e date the Investig Event diagnosis s unknown, enter s tiagnosis, when kn up report nt per line. If event is	Month gator be r syndrou igns / syn own, in a s fatal, en is not acce	ecame a me mptoms a follow-	ware of this inform	nation: Day	Month_ Check only if event occurred before first dose of drug under	event serious?	ar If serious enter Serious Criteria code	Is there a	reason may ha rug un d dministe	able po ve bee erstuo erthe A illed	ossibility en caus dy or an Imgen di <b>Prefili</b> e	ed b Amg rugu	y gen d inders Auton	Event evice study?	of Event Resolved Not resolved Fatal	if event is related to study procedure
and start da 3. ADVER Provide the Adverse If diagnosis is and provide d List one even cause of eeat	ate: Day I <b>REVENT</b> date the Investig Event <u>diagnosis</u> of s unknown, enter si liagnosis, when kn up report th per line. If event ki th. Entry of "death" I	Month gator be r syndrou igns / syn own, in a s fatal, en is not acce	ecame a me mptoms a follow-	ware of this inform	nation: Day Date Ended	Month_ Check only if event occurred before first dose of drug	Ye	ar If serious enter Serious Criteria code (see codes	Is there a Amgen d used to a Repathaf	mayha rugundi dministe b Prel b Syri	able po ve bee erstuo erthe A illed nge	ossibility en caus dy or an Amgen di Prefilk Autoinje	ed b Amg rugu ed ctor	y gen d nders Auton Mini-D	Event evice study? nated Doser	of Event Resolved Not resolved Fatal	ifeventis related to study procedure eg,
and start da 3. ADVER Provide the Adverse If diagnosis is and provide d List one even cause of eeat	ate: Day I <b>REVENT</b> date the Investig Event <u>diagnosis</u> of s unknown, enter si liagnosis, when kn up report th per line. If event ki th. Entry of "death" I	Month gator be r syndrou igns / syn own, in a s fatal, en is not acce	ecame a me mptoms a follow-	ware of this inform	nation: Day Date Ended	Month_ Check only if event occurred before first dose of drug under	event serious?	ar If serious enter Serious Criteria code (see codes	Is there a Amgen d used to a	mayha rugundi dministe b Prel b Syri	able po ve bee erstuo erthe A illed nge	ossibility en caus dy or an Imgen di <b>Prefili</b> e	ed b Amg rugu ed ctor	y gen d nders Auton Mini-D	Event evice study? nated Doser	of Event Resolved Not resolved Fatal	ifeventis related to study procedure eg,
and start da 3. ADVER Provide the Adverse If diagnosis is and provide d List one even cause of eeat	ate: Day I <b>REVENT</b> date the Investig Event <u>diagnosis</u> of s unknown, enter si liagnosis, when kn up report th per line. If event ki th. Entry of "death" I	Month gator be r syndrou igns / syn own, in a s fatal, en is not acce	ecame a me mptoms a follow-	ware of this inform	nation: Day Date Ended	Month_ Check only if event occurred before first dose of drug under	Is event serious?	ar If serious enter Serious Criteria code (see codes	Is there a Amgen d used to a Repathaf	mayha rugundi dministe b Prel b Syri	able po ve bee erstuo erthe A illed nge	ossibility en caus dy or an Amgen di Prefilk Autoinje	ed b Amg rugu ed ctor	y gen d nders Auton Mini-D	Event evice study? nated Doser	of Event Resolved Not resolved Fatal	ifeventis related to study procedure eg,
and start da 3. ADVER Provide the Adverse If diagnosis is and provide d List one even cause of eeat	ate: Day I <b>REVENT</b> date the Investig Event <u>diagnosis</u> of s unknown, enter si liagnosis, when kn up report th per line. If event ki th. Entry of "death" I	Month gator be r syndrou igns / syn own, in a s fatal, en is not acce	ecame a me mptoms a follow- nter the	ware of this inform	nation: Day Date Ended	Month_ Check only if event occurred before first dose of drug under	Yes PYes PYes PYes	ar If serious enter Serious Criteria code (see codes	Is there a Amgen d used to a Repathaf	mayha rugundi dministe b Prel b Syri	able po ve bee erstuo erthe A illed nge	ossibility en caus dy or an Amgen di Prefilk Autoinje	ed b Amg rugu ed ctor	y gen d nders Auton Mini-D	Event evice study? nated Doser	of Event Resolved Not resolved Fatal	ifeventis related to study procedure eg,
and start da 3. ADVER Provide the Adverse If diagnosis is and provide d List one even cause of eeat	ate: Day I <b>REVENT</b> date the Investig Event <u>diagnosis</u> of s unknown, enter si liagnosis, when kn up report th per line. If event ki th. Entry of "death" I	Month gator be r syndrou igns / syn own, in a s fatal, en is not acce	ecame a me mptoms a follow- nter the	ware of this inform	nation: Day Date Ended	Month_ Check only if event occurred before first dose of drug under	Yes INO Ves	ar If serious enter Serious Criteria code (see codes	Is there a Amgen d used to a Repathaf	mayha rugundi dministe b Prel b Syri	able po ve bee erstuo erthe A illed nge	ossibility en caus dy or an Amgen di Prefilk Autoinje	ed b Amg rugu ed ctor	y gen d nders Auton Mini-D	Event evice study? nated Doser	of Event Resolved Not resolved Fatal	ifeventis related to study procedure eg,
and start da 3. ADVER Provide the Adverse If diagnosis and provide d List one ever cause of eeat	ate: Day   RSE EVENT a date the Investig Event diagnosis o s unknown, enter s tiagnosis, when kn up report th per line. If event i th. Entry of "death" I as this is an outcom	Month gator be r syndrou igns / syn own, in a s fatal, en is not acce	ecame a me mptoms a follow- nter the	ware of this inform Date Started Day Month Year	Date Ended	Month_ Check only if event occurred before first dose of drug under study	Yes PYes PYes PYes	ar If serious enter Serious Criteria code (see codes	Is there a Amgen d used to a Repathaf	n reason: may ha rug unde dministe ab Syri s√ No√	able po er stud er stud er the A Nge Yesv	Prefilk Autoinje	ed b Amg rugu ed ctor 'es•	Auton Mini-D Nov	Event evice study? nated Noser Yesv	of Event Resolved Not resolved Fatal Unknown	ifeventis related to study procedure eg,
and start da 3. ADVER Provide the Adverse If diagnosis is and provide d List one even cause of eeat Serious	ate: Day   REEVENT a date the Investig Event diagnosis o s unknown, enter si liagnosis, when kn up report nt per line. If event is h. Entry of "death", as this is an outcom	Month	Ye	ware of this inform Date Started Day Month Year 03 Required	Date Ended	Month_ Check only if event occurred before first dose of drug under study	Yes No No No No No No No	ar If serious enter Serious Criteria code (see codes	Is there a Amgen d used to a Repathaf	Pretable Syri	able po ve be erstuc rthe A illed nge Yesv	Prefille Autoinje Nov Y	ed b Amg rugu ed ctor 'es• ano	y gen d nders Auton Mini-C Nov	Event evice study? nated Noser Yesv	of Event Resolved Not resolved Fatal Unknown	ifeventis related to study procedure eg, biopsy
and start da 3. ADVER Provide the Adverse If diagnosis is and provide d List one ever cause of eeat Serious Criteria:	Ate: Day   <b>REVENT</b> a date the Investig Event diagnosis o s unknown, enter si liagnosis, when kn up report nt per line. If event is h. Entry of "death" as this is an outcom 01 Fatal 02 Immediately li	Month gator be r syndron igns / syn own, in a s fatal, ern is not acce re.	ecame a me mptoms a follow- nter the eptable,	ware of this inform Ware of this inform Date Started Day Month Year 03 Required 04 Persister	Date Ended Day Month Year Uprolonged hospitali tor significant disat	Month_ Check only if event occurred before first dose of drug under study	Peserious ?	ar f serious criteria code (see codes below)	Is there a Amgen d used to a Repatha evolocum Nov Ye	Prelation of the second secon	able po ve be: erstuce arthe A illed nge Yesv Cong Othe	Prefilk Autoinje Nov Y	ed b Amg rug u ed ctor (es•)	y gen di nders Auton Mini-E Nov maly rimp	Event evice study? nated Joser Yesv / birth ortan	of Event Resolved Notresolved Fatal Unknown	if event is related to study procedure eg, biopsy
and start da 3. ADVER Provide the Adverse If diagnosis is and provide d List one ever cause of eeat Serious Criteria:	Ate: Day   <b>REVENT</b> a date the Investig Event diagnosis o s unknown, enter si liagnosis, when kn up report nt per line. If event is h. Entry of "death" as this is an outcom 01 Fatal 02 Immediately li	Month gator be r syndron igns / syn own, in a s fatal, err is not acce re. if e-threat lized o	ecame a me mptoms a follow- nter the eptable, tening r was	ware of this inform Date Started Day Month Year 03 Required 04 Persister a hospitalizatio	Date Ended Day Month Year Uprolonged hospitali tor significant disat	Month_ Check only if event occurred before first dose of drug under study	Peserious ?	ar f serious criteria code (see codes below)	Is there a Amgen d used to a evoloame Nor Ye	Pretable	able po ve bee erstuce rthe A nope Yesv Cong Othe	Prefille Autoinje Nov Y	ed b Amg rug u ed ctor (es•)	y gen di nders Auton Mini-E Nov maly rimp	Event evice study? nated Joser Yesv / birth ortan	of Event Resolved Notresolved Fatal Unknown	if event is related to study procedure eg, biopsy
and start da 3. ADVER Provide the Adverse If diagnosis is and provide d List one ever cause of eeat Serious Criteria:	Ate: Day   <b>REVENT</b> a date the Investig Event diagnosis o s unknown, enter si liagnosis, when kn up report nt per line. If event is h. Entry of "death" as this is an outcom 01 Fatal 02 Immediately li	Month gator be r syndroi igns / syn own, in a s fatal, en is not acce the the the the the the the the the th	ecame a me mptoms a follow- nter the eptable,	ware of this inform Date Started Day Month Year 03 Required 04 Persister a hospitalizatio	Date Ended Day Month Year Uprolonged hospitali tor significant disat	Month_ Check only if event occurred before first dose of drug under study	Peserious ?	ar f serious criteria code (see codes below)	Is there a Amgen d used to a evoloame Nor Ye	reason: may ha rug und- dministe b Prel b Syri s Nov 05 06 05 06 05 06	able po ve bee erstuce rthe A nope Yesv Cong Othe	prefile Prefile Autoinje Nor Y penital r medi	ed b Amg rug u ed ctor (es•)	y gen d nders Auton Mini-C Nov maily rimp	Event evice study? nated Joser Yesv / birth ortan	of Event Resolved Notresolved Fatal Unknown	if event is related to study procedure eg, biopsy
and start da 3. ADVER Provide the Adverse If diagnosis is and provide d List one ever cause of eeat Serious Criteria:	ate:       Day	Month gator be r syndroi igns / syn own, in a s fatal, en is not acce the the the the the the the the the th	ecame a memptoms a follow- nter the eptable, tening r was Admitte	ware of this inform ware of this inform Date Started Day Month Year 03 Required 04 Persister a hospitalizatio	Date Ended Day Month Year Uprolonged hospitali tor significant disat	Month_ Check only if event occurred before first dose of drug under study	Peserious ?	ar f serious criteria code (see codes below)	Repatra  Repatra  Nov Ye	reason: may ha rug und- dministe b Prel b Syri s Nov 05 06 05 06 05 06	able po ve ber er stud er the A illed Yesv Cong Othe es, pl	prefile Prefile Autoinje Nor Y penital r medi	ed b Amg rug u ed ctor (es• anou cally com	y gen d nders Auton Mini-C Nov maily rimp	Event evice study? nated Joser Yesv / birth ortan	of Event Resolved Notresolved Fatal Unknown	if event is related to study procedure eg, biopsy

FORM-099346

Page 1 of 3

Version 1.0 Effective Date: 1 February 2016



<b>AMGEN</b> Study # 20150162	Electronic Adverse Event Contingency Report Form					
Repatha <sup>®</sup> (evolocumab)		<u>F</u>	or Restricted	Jse		
	Site Number	Subjec	t ID Number			
9. OTHER RELEVANT TESTS (			-	sts? □No □Yes Ify		
Date Day Month Year	Additional Test	s	Re	esults	Units	
10. CASE DESCRIPTION (Provi			section 3) Provide	additional pages if ne	cessary. For each	
event in section 3, where relations	nip=Yes, please pro	ovide rationale.				
<u> </u>						
Signature of Investigator or Designee			Title		Date	
gaure et intestigator of Designee	-					
I confirm by signing this report that the in						
causality assessments, is being provided t a Qualified Medical Person authorized by						

FORM-099346

Page 3 of 3

Version 1.0 Effective Date: 1 February 2016

Page 49 of 60



## Appendix D. Additional Safety Reporting Information

Adverse Event Severity Scoring System

Grade	Amgen Standard Adverse Event Severity Scoring System
1	MILD: Aware of sign or symptom, but easily tolerated
2	MODERATE: Discomfort enough to cause interference with usual activity
3	SEVERE: Incapacitating with inability to work or do usual activity

EUROCAT Subgroups	ICD10-BPA	ICD9-BPA	Comments	Excluded	Excluded	Subgroup
				minor	minor	binary
				anomalies	anomalies	variable
				post-2005	pre-2005	number (al)
All anomalies *	Q-chapter,	74, 75,		Exclude all	Exclude all	al1
	D215, D821,	27910,		minor	minor	
	D1810 <sup>°</sup> , P350,	2281^,		anomalies as	anomalies as	
	P351, P371	76076,		specified in	specified in	
		76280, 7710,		Guide 1.4,	Guide 1.2	
		7711, 77121		section 3.2	(ICD9 and ICD10)	
Nervous system	Q00, Q01,	740, 741,		Q0461, Q0782	100107	al2
	Q02, Q03,	742		. , .		
	Q04, Q05,					
	Q06, Q07					
Neural Tube Defects	Q00, Q01,	740, 741,				al3
An an an a ball an and	Q05	7420				-14
Anencephalus and similar	Q00	740				al4
Encephalocele	Q01	7420	Exclude if associated			al5
			with anencephalus			
			subgroup			
Spina Bifida	Q05	741	Exclude if associated			al6
			with anencephalus or			
			encephalocele			
		7423	subgroups			
Hydrocephalus	Q03	7423	Exclude			al7
			hydranencephaly			
			74232. Exclude			
			association with NTD			
Microcephaly	Q02	7421	subgroup Exclude association			al8
wierocephary	0,02	/421	with NTD subgroup			810
Arhinencephaly /	Q041, Q042	74226				al9
holoprosencephaly						
Eye	Q10-Q15	743		Q101-Q103, Q105, Q135	74365	al10
Anophthalmos /	Q110, Q111,	7430, 7431				al11
microphthalmos	Q112					
Anophthalmos	Q110, Q111	7430				al12
Congenital cataract	Q120	74332				al13
Congenital glaucoma	Q150	74320				al14
Ear, face and neck	Q16, Q17,	744		Q170-Q175,	74411, 74412,	al15
	Q18			Q179, Q180-	7443, 74491	
				Q182, Q184-		
				Q187, Q1880,		
				Q189		

## Appendix E. EUROCAT Subgroups of Congenital Anomalies

#### Product: Evolocumab Protocol Number: 20150162 Date: 18 December 2018

			minor	minor	1
					binary
			anomalies post-2005	anomalies pre-2005	variable number (al)
Q20-Q26	745, 746,	Exclude PDA with GA	Q2111,	Q250, 7470 if	al17
	7470-7474	<37 weeks	Q250 if GA	GA <37 weeks	
		Exclude peripheral	<37 weeks,	••	
		pulmonary artery	Q2541,		
		stenosis with GA < 37	Q256 if GA<37		
		weeks	weeks,		
			Q261		
					al97
		outlet right ventricle			
	· · ·				
-					al18
0,200	74500				9110
0201	No code				al109
Q203	74510				al19
Q204	7453				al20
Q210	7454				al21
Q211	7455		Q2111		al22
Q212	7456				al23
Q213	7452				al24
Q224	7461				al25
					al26
Q221	74601				al27
0000	74600				-120
Q220	/4600				al28
0220	7462	ICD9 PPA has no codo			al29
0,250	7405				8125
0232 0233	7465 7466	TOT atresia			al110
0,252, 0,255	/105,/100				0.110
0234	7467				al30
0,251					0.50
Q226	No code				al31
Q251	7471				al32
Q252	74720				al111
Q262	74742				al33
0250	7470	Livebirths only			21100
4250	/4/0	Livebirths only			al100
0300, 032-	7480, 7484	Exclude Q336	0314, 0315	Q309, 74819	al34
Q34			Q320, Q331		
-	74852,		,		
	74858, 7486,				
	7488				
Q300	7480				al35
Q3380	No code				al36
	Q200, Q201, Q203, Q204, Q212, Q213, Q220, Q224, Q230, Q232, Q233, Q234, Q251, Q252, Q200 Q201 Q201 Q201 Q201 Q203 Q204 Q210 Q211 Q212 Q213 Q224 Q225 Q221 Q226 Q221 Q220 Q230 Q230 Q232, Q233 Q234 Q234 Q234 Q250 Q250 Q300, Q32- Q34	Q200, Q201, Q203, Q204, Q203, Q204, Q212, Q213, Q220, Q224, Q212, Q223, Q220, Q224, Q230, Q232, Q262         74510, 7452, 74510, 7452, 74510, 7452, 7465, 7466, Q233, Q234, 7467, 7471, Q251           Q200         74500           Q201         No code           Q201         74510           Q201         No code           Q201         74510           Q201         No code           Q201         7453           Q210         7453           Q211         7455           Q212         7456           Q213         7452           Q224         7461           Q225         7462           Q221         74601           Q220         74601           Q220         7463           Q230         7465, 7466           Q230         7467           Q226         7471           Q250         7472           Q250         7470           Q262         74742           Q250         7470           Q250         7470           Q250         7470           Q300, Q32- Q34         7480, 7484, 74850, 74858, 7486	7470-7474       <37 weeks	7470-7474         <37 weeks	7470-7474         37 weeks sculde peripheral pulmonary artery stenosis with GA < 37 weeks, 02561         GA <37 weeks, 02561         GA <37 weeks, 02561           0200, 0201, 0203, 0204, 74510, 7452, 7460, 7452, 74600, 7463, 0225, 0226, 7465, 7466, 7461, 7472, 7461, 7472, 7462, 7472, 74720, 74742         ICD-BPA has no code for HRH and double outlet right ventricle         ICD-BPA has no code for HRH and double outlet right ventricle         ICD-BPA has no code for HRH and double outlet right ventricle         ICD-BPA has no code for HRH and double outlet right ventricle         ICD-BPA has no code for HRH and double outlet right ventricle         ICD-BPA has no code for HRH and double outlet right ventricle         ICD-BPA has no code for HRH and double outlet right ventricle         ICD-BPA has no code for HRH and double outlet right ventricle         ICD-BPA has no code for HRH and double outlet right ventricle         ICD-BPA has no code for ICD-BPA has no code for atresia         ICD-BPA has no code for atresia

EUROCAT Subgroups	ICD10-BPA	ICD9-BPA	Comments	Excluded minor anomalies post-2005	Excluded minor anomalies pre-2005	Subgroup binary variable number (al)
Oro-facial clefts	Q35-Q37	7490, 7491, 7492	Exclude association			al101
			with			
			holoprosencephaly			
			or anencephaly			
			subgroups			
Cleft lip with or	Q36, Q37	7491, 7492	Exclude association			al102
without cleft			with			
palate			holoprosencephaly			
			or anencephaly			
			subgroups			
Cleft palate	Q35	7490	Exclude association			al103
			with cleft lip			
			subgroup. Exclude			
			association with			
			holoprosencephaly			
			or anencephaly			
			subgroups			
Digestive system	Q38-Q45,	750, 751, 7566		Exclude Q381,	Q381, Q401,	al40
	Q790			Q382, Q3850,	7500, 7506	
				Q400, Q401,		
				Q4021, Q430,		
				Q4320,		
				Q4381,		
				Q4382		
Oesophageal atresia	Q390-Q391	75030-75031				al41
with or without						
trachea-						
oesophageal						
fistula						
Duodenal atresia or	Q410	75110	Exclude if also			al42
stenosis			annular pancreas			
			subgroup			
Atresia or stenosis	Q411-Q418	75111-75112				al43
of other parts of						
small intestine						
Ano-rectal atresia	Q420-Q423	75121-75124				al44
and stenosis						
Hirschsprung's	Q431	75130-75133				al45
disease						
Atresia of bile ducts	Q442	75165				al46
Annular pancreas	Q451	75172				al47
Diaphragmatic	Q790	75661				al48
hernia						
Abdominal wall	Q792, Q793,	75671, 75670,				al49
defects	Q795	75679				
Gastroschisis	Q793	75671				al50
Omphalocele	Q792	75670				al51
Urinary	Q60-Q64,	75261, 753,		Q610, Q627,		al52
	Q794	75672		Q633		
Bilateral renal	Q601, Q606	75300	Exclude unilateral			al53
agenesis						
including Potter						
syndrome						
Multicystic renal	Q6140,	75316				al54
dysplasia	Q6141					
Congenital	Q620	75320				al55
hydronephrosis	-					
Bladder exstrophy	Q640, Q641	75261, 7535				al56
and / or epispadia		,				
Posterior urethral	Q6420, Q794	75360, 75672				al57
valve and / or	20120, 0104					a
valve and / Of	1	1	1	1	1	1

EUROCAT Subgroups	ICD10-BPA	ICD9-BPA	Comments	Excluded	Excluded	Subgroup
concern casproups				minor	minor	binary
				anomalies	anomalies	variable
				post-2005	pre-2005	number (al)
Genital	Q50-Q52,	7520-7524,		Q523, Q525,	Q540, 75260#	al58
	Q54-Q56	75260, 75262,		Q527, Q5520,		
		7527-7529		Q5521		
Hypospadias	Q54	75260			Q540, 75260	al59
Indeterminate sex	Q56	7527				al60
Limb	Q65-Q74	7543-7548, 755		Q653-Q656,	75432, 75452,	al61
				Q662-Q669,	75460, 75473,	
				Q670-Q678,	75481, 75560	
				Q680, Q6810,		
				Q6821, Q683-		
				Q685, Q7400		100
Limb reduction	Q71-Q73	7552-7554				al62
defects		75.450				100
Club foot – talipes	Q660	75450				al66
equinovarus	0.000	75.430				-167
Hip dislocation and / or dyspasia	Q650-Q652, Q6580,	75430				al67
or dyspasia						
Polydactyly	Q6581 Q69	7550				al68
Syndactyly	Q70	7551				al69
Other anomalies /	0/0	7551				alog
syndromes						
Skeletal dysplasias	Q7402, Q77,	No code				al104
okeletal uyspiasias	Q7800,	No code				a1104
	Q782-Q788,					
Craniosynostosis	Q750	75600				al75
Congenital	Q7980	76280				al76
constriction bands	0.000	/0200				
/ amniotic band						
Situs inversus	Q893	7593				al79
Conjoined twins	Q894	7594				al80
Congenital skin	Q80-Q82	7571, 7573		Q825, Q8280	Q825, Q8280,	al81
disorders					Q8281,	
					75731, 75738	
VATER/VACTERL	Q8726	759895				al112
Vascular disruption	Q0435,	No code				al113
anomalies	Q411, Q412,					
	Q418, Q710,					
	Q712, Q713,					
	Q720, Q722,					
	Q723, Q730,					
	Q793, Q795,					
	Q7980,					
	Q7982,					
	Q8706					
Laterality anomalies	Q206, Q240,	No code				al114
	Q3381,					
-	Q890, Q893	No				-100
Teratogenic	Q86, P350,	No code				al82
syndromes with	P351, P371					
malformations Fetal alcohol	0050	76076				-102
Fetal alcohol syndrome	Q860	76076				al83
	Q8680	No codo				al84
Valproate syndrome Maternal infections	Q8680 P350, P351,	No code 7710, 7711,				al84 al86
resulting in	P350, P351, P371	7710, 7711,				8100
malformations						
manormations		l	1		L	

## Appendix F. Pregnancy Outcome Definitions\*

Pregnancy outcome: the end products of pregnancy which include three main categories:

- Fetal death, termination of pregnancy and live birth.
- Fetal death (intrauterine death, in utero death): death prior to complete expulsion or extraction from its mother of a product of conception, irrespective of the duration of pregnancy; the death is indicated by the fact that after such separation the fetus does not show any evidence of life (WHO ICD 10).

Early fetal death (before 22 completed weeks of gestation) comprises ectopic pregnancy and miscarriage and late fetal death (after 22 completed weeks of gestation) is known as stillbirth.

- Ectopic pregnancy: extrauterine pregnancy, early fetal death most often in the Fallopian tube.
- Miscarriage: spontaneous abortion, molar pregnancy.
- Termination of pregnancy (induced abortion, elective abortion): artificial interruption of pregnancy.
- Live birth: the complete expulsion or extraction from its mother of a product of conception, irrespective of the duration of the pregnancy which, after such separation, breathes or shows any evidence of life. (WHO ICD 10).
- Gestational age or length: the duration of gestation is measured from the first day of the last normal menstrual period. Gestational age is expressed in completed days or completed weeks (eg, events occurring 280 to 286 days after the onset of the last menstrual period are considered to have occurred at 40 weeks of gestation).
- Last menstrual period (abbreviation LMP): according to international consensus, the gestational age is measured from the first day of the LMP.
- Birth weight: the initial weight of the infant at birth.
- Pre-term birth (previous term: premature birth): less than 37 completed weeks (less than 259 days) of gestation.

Term birth: from 37 to less than 42 completed weeks (259 to 293 days).

- Post-term birth: 42 completed weeks or more (294 days or more).
- Low birth weight: less than 2,500 gram (up to and including 2,499 g) of body weight of the newborn at birth.
- Intrauterine growth retardation (small for gestational age): the observed weight of a live born infant or size of a fetus is lower than expected on the basis of gestational age.

\*EMEA/CHMP Guideline on Exposure to Medicinal Products During Pregnancy



			1	Fiming of Rep	oatha <sup>®</sup> expos	ure		
		Exposed but stopped prior			Exposed at conception and during 1 <sup>st</sup> trimester	Exposed	Exposure during breastfeeding	
	Unexposed (N = x)	to conception (N = x)	trimester (N = x)	trimesters (N = x)	trimesters (N = x)	pregnancy (N = x)	only (N = x)	breastfeeding (N = x)
	(N – X) n (%)	(N – X) n (%)	(N – X) n (%)	(N – X) n (%)	(N – X) n (%)	(N – X) n (%)	(N – X) n (%)	(N – X) n (%)
Pregnancies enrolled pre-partum								
All outcomes	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Live birth without congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Live birth with congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Neonatal death without congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Neonatal death with congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Stillbirth without congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Stillbirth with congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Miscarriage without congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Miscarriage with congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Termination of pregnancy without congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Termination of pregnancy with congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Ectopic pregnancy	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Molar pregnancy	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Pregnancy continuing at time of data cut-off	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Pregnancies enrolled post-partum	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
All outcomes	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Live birth without congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Live birth with congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Neonatal death without congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Neonatal death with congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)

## Appendix G. Template Summary Table of Pregnancy Outcome



			1	liming of Re	oatha <sup>®</sup> expos	ure		
	Unexposed (N = x)	Exposed but stopped prior to conception (N = x)	Exposure in 1st trimester (N = x)	n Exposure ir 2 <sup>nd</sup> /3rd trimesters (N = x)	Exposed at conception and during 1 <sup>st</sup> trimester but stopped in 2nd/3rd trimesters (N = x)	Exposed	Exposure during breastfeeding only (N = x)	Exposure during both pregnancy and breastfeeding (N = x)
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Stillbirth without congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Stillbirth with congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Miscarriage without congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Miscarriage with congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Termination of pregnancy without congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Termination of pregnancy with congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Ectopic pregnancy	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Molar pregnancy	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)

Country	Live Births (2017)	% of Total live births	Expected N live births of unexposed mothers	Country cap on unexposed pregnancies
Australia	309,142	8.0	48	150
Austria	87,633	2.3	14	136
Belgium	119,690	3.1	19	150
Czech Republic	114,405	3.0	18	150
Denmark	61,397	1.6	10	95
Greece	88,523	2.3	14	138
Italy	458,151	11.9	71	150
Netherlands	169,200	4.4	26	150
Norway	56,633	1.5	9	88
Slovakia	57,969	1.5	9	90
South Africa	989,318	25.6	154	150
Spain	390,024	10.1	61	150
Sweden	115,416	3.0	18	150
Switzerland	87,381	2.3	14	136
UK	755,043	19.6	117	150
Total	3,859,925	100.0	600	NA <sup>a</sup>

## Appendix H. Calculation of Percentage of Live Births

Sources:

Eurostat (2018) Live births and crude birth rate: https://ec.europa.eu/eurostat/tgm/table.do?tab=table&init=1&language=en&pcode=tps00204&plugin=1 Australian Bureau of Statistics (2018) Births, Australia, 2017:

http://www.abs.gov.au/ausstats%5Cabs@.nsf/0/8668A9A0D4B0156CCA25792F0016186A?Opendocument

Statistics South Africa (2018) Recorded live births, 2017. http://www.statssa.gov.za/?p=11478 Footnote:

<sup>a</sup> maximum number of unexposed pregnancies will be capped at 600 across all countries, therefore a minimum of 4 countries will be represented among unexposed pregnancies



## Appendix I. Pregnancy and Lactation Worksheets

AMGEN <sup>®</sup> Pregnancy Notification Worksheet							
Fax		n to the Country-r	espective S				
1. Case Administrative Inf Protocol/Study Number: 2015016 Study Design: Interventional	ormation 2		Prospective	Retrospective)			
2. Contact Information Investigator Name Phone () Institution Address	Fax (	)		Site # Email			
3. Subject Information Subject ID #Subject Gender: Female Male Subject DOB: mm/ dd/ yyyy							
4. Amgen Product Exposu	Ire						
Amgen Product	Dose at time of conception	Frequency	Route	Start Date			
				mm/dd/yyyy			
Was the Amgen product (or st If yes, provide product (or Did the subject withdraw from	study drug) stop da	te: mm/dd		l			
5. Pregnancy Information         Pregnant female's LMP         Pregnant female's LMP         mm       / dd         / dd       / yyyy         Unknown         Estimated date of delivery       mm         / dd       / yyyy         Unknown         If N/A, date of termination (actual or planned) mm       / / dd         / dd       / yyyy         Has the pregnant female already delivered?       Yes         No       Unknown         If yes, provide date of delivery:       mm         // dd       / / yyyy         Was the infant healthy?       Yes         No       Unknown         N/A         If any Adverse Event was experienced by the infant, provide brief details:							

Form Completed by:	
Print Name:	Title:
Signature:	Date:

.....

Effective Date: March 27, 2011

Page 1 of 1



## AMGEN<sup>\*</sup> Lactation Notification Worksheet

Fax Completed Form to the		ve Safety Fax Line ELECT OR TYPE IN		er fax number
1. Case Administrative Inf	ormation			
Protocol/Study Number: 201501	/62			
Study Design: 🗌 Interventional		(If Observational:	Prospective	Retrospective)
2. Contact Information				
Investigator Name				Site #
Phone ()				Email
Institution				· · · · · · · · · · · · · · · · · · ·
Address				
3. Subject Information				
Subject ID #	Subject Date	of Birth: mm	/dd/y	vyy
4. Amgen Product Exposu	ure			
	Dose at time of			······
Amgen Product	breast feeding	Frequency	Route	Start Date
				mm /dd /yyyy
Was the Amgen product (or st	tudy drug) discontinu	ed? 🗌 Yes 📃 N	lo	
If yes, provide product (or	r study drug) stop da	te: mm/dd	_/yyyy	
Did the subject withdraw from	the study? 🔲 Yes	No		
5. Breast Feeding Informa	tion			
5. Dreast recuing morna	uon			
Did the mother breastfeed or provi	de the infant with pu	mped breast milk whi	le actively tak	ing an Amgen product? 🗌 Yes 📄 No
If No, provide stop date: m	ım /dd	/www		
Infant date of birth: mm/dd/yyyy				
		Infant gender: 🔲 Female 🔄 Male		
	Vale			
		N/A		
Infant gender: Female M Is the infant healthy? Yes	No 🗌 Unknown	_		
Infant gender: 🗌 Female 🗌 N	No 🗌 Unknown	_	rief details:	
Infant gender: Female M Is the infant healthy? Yes	No 🗌 Unknown	_	rief details:	

Form Completed by:	
Print Name:	Title:
Signature:	Date:

.....

Effective Date: 03 April 2012, version 2.

Page 1 of 1

## Amendment 1

# Protocol Title: A Multinational Observational Study to Evaluate the Safety of Repatha<sup>®</sup> in Pregnancy

Amgen Protocol Number Evolocumab 20150162

Amendment Date: 18 December 2018

## Rationale:

This protocol is being amended to:

- Update the study design schema for clearer and more precise presentation
- Update the number of sites participating in the study (Section 9.2.2)
- Update inclusion criteria for subject eligibility regarding pregnancy identified retrospectively and multiple pregnancies (Section 9.2.3.1)
- Clarify study follow-up conditions and adverse event collection for pregnant or breastfeeding mothers who are exposed to Repatha<sup>®</sup>
- Group variables/data/outcomes to be collected into categories for better presentation
- Update the product indication in Section 7.1 (Diseases and Therapeutic Area) and Abstract
- Add relevant text to define the maximum size of the unexposed cohort overall, and to ensure geographical representativeness of the unexposed cohort (Section 9.5 and Appendix H)
- Update the stratified analyses for clearer description and more precise presentation
- Update safety reporting requirements (Section 11.2), by including a definition for Investigator Date of Awareness
- Update the template summary table of pregnancy outcome (Appendix G)
- Make editorial and administrative changes for grammatical reasons as well as for internal consistency within the protocol.

## **Description of Changes:**

#### Section: Global

Change: The Amgen global version date was changed from 17 May 2016 to

## 18 December 2018

## Section: Global

**Change:** Editorial, typographical, and formatting changes were made throughout the document.

## Section: Title Page, Summary Table of Study Protocol

## Replace:

Title	A Multinational Observational Study to Evaluate the Safety of Repatha <sup>®</sup> in Pregnancy
Protocol version identifier	1.0
Date of last version of the protocol	17 May 2016
EU Post Authorisation Study (PAS) Register No	Registration occurs after Amgen internal approval of the protocol; must be prior to commencement of first data capture
Active Substance	Evolocumab
Medicinal Product	Repatha®
Product Reference	EU/1/15/1016
Procedure Number	EMA/H/C/3766
Marketing Authorisation Holder(s)	Amgen Europe B.V.
Joint PASS	No

Research Question and Objectives	Research Question: To evaluate outcomes of pregnancy in females diagnosed with familial hypercholesterolaemia (FH), exposed to Repatha® during pregnancy. This includes follow-up of their infants to the age of 12 months. Primary Objective: To describe congenital anomalies in infants of females with FH exposed to Repatha® within 15 weeks prior to or during pregnancy, followed to the age of 12 months. Secondary Objectives: To describe outcomes of pregnancy (other than congenital anomalies) in females with FH exposed to Repatha® within 15 weeks prior to and/or during pregnancy; To describe outcomes of pregnancy in females with FH not exposed to Repatha® within 15 weeks prior to and/or during pregnancy; To describe outcomes (other than congenital anomalies) in infants up to the age of 12 months, born to females diagnosed with FH
Countries of Study	Europe (multicountry), South Africa, Australia
Author	PPD Amgen Ltd 240 Science Park Cambridge CB4 0WD UK

## Marketing Authorisation Holder

Marketing authorisation holder(s)	Amgen Europe B.V.
MAH Contact	PPD Amgen Ltd Science Park Cambridge CB4 0WD UK PPD

## With:

Title	A Multinational Observational Study to Evaluate the Safety of Repatha <sup>®</sup> in Pregnancy
Protocol version identifier	2.0
Date of last version of the protocol	17 May 2016
EU Post Authorisation Study (PAS) Register No	EUPAS15153
NCT Number	NCT02906124
Active Substance	Evolocumab
Medicinal Product	Repatha®
Product Reference	EU/1/15/1016
Procedure Number	EMA/H/C/3766
Marketing Authorisation Holder(s)	Amgen Europe B.V.
Joint PASS	No
Research Question and Objectives	Research Question: To evaluate <b>pregnancy and</b> <b>infant</b> outcomes <b>among</b> females diagnosed with familial hypercholesterolaemia (FH), exposed to Repatha <sup>®</sup> during pregnancy. This includes follow-up of their infants to the age of 12 months. Primary Objective: To describe congenital anomalies in infants of females with FH exposed to Repatha <sup>®</sup> within 15 weeks prior to or during pregnancy, followed to the age of 12 months. Secondary Objectives: To describe outcomes of pregnancy (other than congenital anomalies) in females with FH exposed to Repatha <sup>®</sup> within 15 weeks prior to and/or during pregnancy; To describe outcomes of pregnancy in females with FH not exposed to Repatha <sup>®</sup> within 15 weeks prior to and/or during pregnancy; To describe <b>health and developmental</b> outcomes in infants up to the age of 12 months, born to females diagnosed with FH <b>and exposed/unexposed to Repatha<sup>®</sup> during</b> <b>pregnancy and/or breastfeeding.</b>
Countries of Study Author	Europe (multicountry), South Africa, Australia  PPD Amgen Ltd 1 Uxbridge Business Park Sanderson Road Uxbridge UB8 1DH UK



.


## Marketing Authorisation Holder


Marketing authorisation holder(s)	Amgen Europe B.V.
MAH Contact	PPD Amgen Ltd 1 Uxbridge Business Park Sanderson Road Uxbridge UB8 1DH UK PPD



## Section: Study Design Schema

**Replace:** 






Individual subject follow-up period



With:

Enrolment occurs at the time of identification of the pregnancy by the study site



FH = familial hypercholesterolaemia

## Section: 4 Abstract, Study Background and Rationale, Paragraph 3

#### Add:

In Europe, Repatha<sup>®</sup> is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet, in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated (Repatha<sup>®</sup> EPAR, EMA website). **Repatha is also indicated in adults and adolescents aged 12 years and over with homozygous** familial hypercholesterolaemia in combination with other lipid-lowering therapies. Additionally, Repatha is indicated in adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors: in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or, alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

## Section: 4 Abstract, Study Background and Rationale, Paragraph 4

## **Delete:**

Based on modality, mechanism of action, <del>published human data</del> and nonclinical studies, safety issues are not expected with Repatha<sup>®</sup> use during pregnancy.

## Section: 4 Abstract, Study Background and Rationale, Paragraph 6

## Replace:

Safety of Repatha<sup>®</sup> whilst breast-feeding is similarly considered to be missing information. Published literature support the expectation of a low risk of maternally-administered monoclonal antibodies resulting in pharmacologically relevant systemic exposures in breastfed infants, the milk-to-serum concentration ratio of IgG being low (Kim et al, 1992; Telemo et al., 1996; Ostensen and Eigenmann, 2004; Mahadevan et al, 2005; Vasiliauskas et al, 2006).



## With:

**Similarly, s**afety of Repatha<sup>®</sup> whilst breast-feeding is considered to be missing information. Published literature **indicates that in general, there is** a low risk of maternally-administered monoclonal antibodies resulting in pharmacologically relevant systemic exposures in breastfed infants, the milk-to-serum concentration ratio of IgG being low (Kim et al, 1992; Telemo et al., 1996; Ostensen and Eigenmann, 2004; Mahadevan et al, 2005; Vasiliauskas et al, 2006).

Section: 4 Abstract, Study Background and Rationale, Paragraph 12

## Replace:

This multinational observational study is expected to enrol female FH patients, identified in collaboration with specialist physicians and patient groups: Females with FH exposed to Repatha<sup>®</sup> during pregnancy and/or breast-feeding will form the exposed cohort, and females with FH unexposed to Repatha<sup>®</sup> during pregnancy and/or breast-feeding will form the internal comparator group. Although no formal comparison of exposed/unexposed subjects is planned, capturing outcomes of pregnancy in a rare population unexposed to Repatha<sup>®</sup> will provide some contemporary point of reference against which to consider outcomes in exposed pregnancies.

## With:

This multinational observational study is expected to enrol female FH patients, identified in collaboration with specialist physicians and patient groups: Females with FH exposed to Repatha<sup>®</sup> during pregnancy and/or breast-feeding will form the exposed cohort, and females with FH unexposed to Repatha<sup>®</sup> during pregnancy and breast-feeding will form the internal comparator group. Although no formal comparison of exposed/unexposed to Repatha<sup>®</sup> will provide contemporary reference **data** against which to consider outcomes in exposed pregnancies. **Due to potentially insufficient data and consequent lack of statistical power, it is unlikely that comparisons between the two groups will provide meaningful results, hence, no formal comparison of exposed/unexposed subjects is planned.** 



## Section: Abstract, Research Question and Objectives, Secondary Objectives

## **Replace:**

- Secondary Objectives:

To describe outcomes of pregnancy (other than congenital anomalies) in females with FH exposed to Repatha<sup>®</sup> within 15 weeks prior to and/or during pregnancy

- To describe outcomes of pregnancy in females with FH not exposed to Repatha<sup>®</sup> within 15 weeks prior to and/or during pregnancy
- To describe outcomes (other than congenital anomalies) in infants up to the age of 12 months, born to females diagnosed with FH and exposed/unexposed to Repatha<sup>®</sup>

## With:

- Secondary Objectives:
  - To describe outcomes of pregnancy (other than congenital anomalies) in females with FH exposed to Repatha<sup>®</sup> within 15 weeks prior to and/or during pregnancy
  - To describe outcomes of pregnancy in females with FH not exposed to Repatha<sup>®</sup> within 15 weeks prior to and/or during pregnancy
  - To describe health and developmental outcomes in infants up to the age of 12 months, born to females diagnosed with FH and unexposed or exposed to Repatha<sup>®</sup> during pregnancy and/or breastfeeding.

## Section: Abstract, Study Population or Data Resource

## Replace:

The study population comprises females in Europe, South Africa and Australia diagnosed with FH and who are identified as being pregnant and/or breast-feeding during the study period, and who provide informed consent to participate in the study. Their infants will also be followed to the age of 12 months.

## With:

The study population comprises females in Europe, South Africa and Australia diagnosed with FH and who are **either** pregnant or breast-feeding during the study period, and who provide informed consent to participate in the study, **if applicable according to local requirements**. Their infants will also be followed to the age of 12 months, following consent by the mother (if applicable per local regulations).

(Note: The therapeutic strategy assigned to each patient enrolled in the study will not be specified within this study protocol. Instead, it will be decided according to routine clinical practice, hence the decision for medicinal prescription will be clearly dissociated from the decision to include the patient in the study).



## Section: Abstract, Summary of Subject Eligibility Criteria, Inclusion Criteria

#### Add:

- Females diagnosed with FH
- Confirmed pregnancy during the study observation period
  - Pregnancies identified retrospectively but within the study period will be included
  - Multiple pregnancies, occurring in the same woman within the study period, will all be included (as separate pregnancies)
- Provided informed consent to follow-up in this study, for subject and their infant(s) born during the study observation period.

## Section: Abstract, Variables

## **Replace:**

- Outcome Variables:
  - Congenital anomaly including congenital abnormality or malformation as defined by EUROCAT (See Appendix E for full list)
  - Complications of pregnancy including:
    - o Pre-eclampsia
    - o Gestational diabetes
  - Outcomes of pregnancy: (See Appendix D for further definition):
    - o Live birth
    - Elective termination (including reason, gestational age)
    - Miscarriage (including gender, anomalies, pathology)
    - Ectopic pregnancy
    - Molar pregnancy
    - o Infant(s) gender; gestational age; birth weight, ; Apgar score
  - Mode of delivery:
    - Normal vaginal delivery
    - o Operative vaginal delivery
    - o Caesarian section
  - Complications of delivery:
    - Abnormal cord gas
    - Abnormal fetal heart rate auscultation
    - Abnormal amniotic fluid
    - o Blood transfusion resulting from post-partum haemorrhage
    - o Thromboembolism



- Exposure Variables:
  - Exposure to Repatha<sup>®</sup> (duration of exposure, doses, dose frequency) within 15 weeks prior to conception and/or during pregnancy and/or whilst breast-feeding
- Other Variables:
  - Baseline:
    - Country of residence; age; education; occupation; height and weight
    - Current pregnancy history (date of last menstrual period; estimated date of delivery; number of fetuses; treatment for infertility)
    - Medical history (FH diagnosis; significant comorbid conditions; family history of congenital disorders)
    - Obstetric history (number of previous pregnancies and outcome; previous maternal pregnancy complications; previous fetal/neonatal abnormalities; history of subfertility)
  - Medications (product, dose, dose dates) taken within 3 months prior to or during pregnancy (excluding medication routinely administered during labour/delivery) and/or breast-feeding
  - Lipid levels (total cholesterol, LDL, HDL, triglycerides)
  - Infant development milestones and health to 12 months of age (growth, hospitalisation, chronic medication)

## With:

## The following types of data/outcomes will be collected:

- Maternal Data:
  - Demographics
  - Current pregnancy history
  - Medical history
  - **Obstetric history**
  - Lipid levels
  - Medications
  - o Congenital anomalies
  - Complications of pregnancy
  - Outcomes of pregnancy
  - Mode of delivery
  - Complications of delivery
- Infant Data:
  - Infant status at delivery
  - Infant health, growth, and developmental outcomes until 12 months of age



 Exposure Data: Exposure to Repatha<sup>®</sup> (duration of exposure, doses, dose frequency) within 15 weeks prior to conception and/or during pregnancy and/or whilst breast-feeding

#### Section: Abstract, Study Sample Size

#### Add:

The Guideline further states that if no increased incidence of malformations is observed within at least 300 first trimester-exposed, prospectively collected pregnancies with known pregnancy outcomes (births or fetopathological examinations) then the conclusion might be reached that the medicinal product is not responsible for a 10-fold or more increase of the overall incidence of malformations. In accordance with the Guideline, this study will endeavour to enrol 300 pregnancies exposed to Repatha in the first trimester. The maximum number of unexposed pregnancies will be limited to a ratio of 2 unexposed to 1 exposed; ie, 600 unexposed pregnancies.

#### Section: 5 Amendments and Updates

Replace:

None

With:

Amendment/Update	Date Performed
Study Protocol Amendment 1	18 December 2018

#### Section: 7.1 Diseases and Therapeutic Area, Paragraph 3

#### Replace:

In Europe, Repatha<sup>®</sup> is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet, in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated (Repatha<sup>®</sup> EPAR, EMA website). Based on modality, mechanism of action, published human data and nonclinical studies, safety issues are not expected with Repatha<sup>®</sup> use during pregnancy.



In Europe, Repatha<sup>®</sup> is indicated in adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors: in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or, alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. Repatha is also indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies (Repatha<sup>®</sup> EPAR, EMA website). Based on modality, mechanism of action, and nonclinical studies, safety issues are not expected with Repatha<sup>®</sup> use during pregnancy.

## Section: 7.1 Diseases and Therapeutic Area, Paragraph 6

## Replace:

Safety of Repatha<sup>®</sup> whilst breast-feeding is similarly considered to be missing information. Published literature support that there is a low risk of maternally-administered monoclonal antibodies resulting in pharmacologically relevant systemic exposures in breastfed infants, the milk-to-serum concentration ratio of IgGs being low (Kim et al, 1992; Telemo et al., 1996; Ostensen and Eigenmann, 2004; Mahadevan et al, 2005; Vasiliauskas et al, 2006).

## With:

**Similarly, s**afety of Repatha<sup>®</sup> whilst breast-feeding is considered to be missing information. Published literature **indicates** that **in general**, there is a low risk of maternally-administered monoclonal antibodies resulting in pharmacologically relevant systemic exposures in breastfed infants, the milk-to-serum concentration ratio of IgGs being low (Kim et al, 1992; Telemo et al., 1996; Ostensen and Eigenmann, 2004; Mahadevan et al, 2005; Vasiliauskas et al, 2006).

## Section: 7.2 Rationale, Paragraph 4

#### Replace:

This multinational observational study is expected to enrol female FH patients, identified in collaboration with specialist physicians and patient groups: Females with FH exposed to Repatha<sup>®</sup> during pregnancy and/or breast-feeding will form the exposed cohort, and



females with FH unexposed to Repatha<sup>®</sup> during pregnancy and/or breast-feeding will form the internal comparator group. Although no formal comparison of exposed/unexposed subjects is planned, capturing outcomes of pregnancy in a rare population unexposed to Repatha<sup>®</sup> will provide some contemporary point of reference against which to consider outcomes in exposed pregnancies.

## With:

This multinational observational study is expected to enrol female FH patients, identified in collaboration with specialist physicians and patient groups:

- Females with FH exposed to Repatha<sup>®</sup> during pregnancy and/or breast-feeding will form the exposed cohort, and
- Females with FH unexposed to Repatha<sup>®</sup> during pregnancy and breast-feeding will form the internal comparator group. Although no formal comparison of exposed/unexposed subjects is planned, capturing outcomes of pregnancy in a rare population unexposed to Repatha<sup>®</sup> will provide contemporary reference data against which to consider outcomes in exposed pregnancies.

## Section: 8.2 Secondary Objectives

## Replace:

- To describe outcomes of pregnancy (other than congenital anomalies) in females with FH exposed to Repatha<sup>®</sup> within 15 weeks prior to or during pregnancy
- To describe outcomes of pregnancy in females with FH not exposed to Repatha<sup>®</sup> within 15 weeks prior to or during pregnancy
- To describe outcomes (other than congenital anomalies) in infants up to the age of 12 months, born to females diagnosed with FH and exposed/unexposed to Repatha<sup>®</sup>

#### With:

- To describe outcomes of pregnancy (other than congenital anomalies) in females with FH exposed to Repatha<sup>®</sup> within 15 weeks prior to or during pregnancy
- To describe outcomes of pregnancy in females with FH not exposed to Repatha<sup>®</sup> within 15 weeks prior to or during pregnancy
- To describe **health and developmental** outcomes in infants up to the age of 12 months, born to females diagnosed with FH and **unexposed or** exposed to Repatha<sup>®</sup> **during pregnancy and/or breastfeeding**.

Section: 9.1 Study Design, Paragraph 1, 3, and 4

#### Replace:

The study is a multinational (Europe, South Africa and Australia) prospective observational cohort study designed to capture data on outcomes of pregnancy in women diagnosed with FH. Within this population, the exposure of interest is administration of Repatha<sup>®</sup> during pregnancy and/or breast-feeding. The primary and secondary outcome measures are congenital anomaly and other outcomes of pregnancy, respectively.

At the individual subject level, data of interest include demographics, medical and obstetric history at the time of confirmation of pregnancy within the study observation period. The subject will be followed for the outcome of pregnancy, including follow-up of the infant(s) to 12 months post-delivery. Data capture may be retrospective if a pregnancy occurring during the study period is detected after delivery.

Study site staff will abstract data from patient notes and entered into the sponsor's electronic database. There will be independent external expert adjudication of adverse outcomes (particularly those associated with congenital anomaly), to ensure consistency and accuracy of reporting. Analyses will be conducted by the sponsor.

#### With:

The study is a multinational (Europe, South Africa and Australia) prospective observational cohort study designed to capture data on outcomes of pregnancy in women diagnosed with FH. Within this population, the exposure of interest is administration of Repatha<sup>®</sup> during pregnancy and/or breast-feeding. The primary and secondary outcome measures are congenital anomaly and other outcomes of pregnancy **or infancy**, respectively.

At the individual subject level, data of interest include demographics, medical and obstetric history at the time of confirmation of pregnancy within the study observation period. The subject will be followed **to determine** the outcome of pregnancy, including follow-up of the infant(s) to 12 months post-delivery. Data capture may be retrospective if a pregnancy occurring during the study period is detected after delivery.

Study site staff will abstract data from patient notes and entered into the sponsor's electronic database. There will be independent external expert adjudication of



congenital anomaly to ensure consistency and accuracy of reporting. Analyses will be conducted by the sponsor.

Section: 9.2.2 Selection and Number of Sites, Paragraph 2

## Replace:

At least 70 sites are expected to participate in the study. As many countries as possible within Europe, as well as South Africa and Australia, are invited and encouraged to participate. Site identification is expected to continue during the course of the study, to maximise the catchment across the FH population and hence the number of potential study subjects.

#### With:

**An estimated 50 to** 70 sites are expected to participate in the study. As many countries as possible within Europe, as well as South Africa and Australia, are invited and encouraged to participate. Site identification is expected to continue during the course of the study, to maximise the catchment across the FH population and hence the number of potential study subjects.

#### Section: 9.2.3.1 Inclusion Criteria

#### Add:

- Females diagnosed with FH
- Confirmed pregnancy during the study observation period
  - Pregnancies identified retrospectively but within the study period will be included
  - Multiple pregnancies, occurring in the same woman within the study period, will all be included (as separate pregnancies)
- Provided informed consent to follow-up in this study, for subject and their infant(s) born during the study observation period

## Section: 9.2.6 Study Follow-up

#### Replace:

Follow-up duration may differ for each individual subject, depending on the outcome of pregnancy: Initial baseline information will be recorded at confirmation of pregnancy and the subject will be followed for outcome of pregnancy. Information on pregnancy outcome, and on infant health at 6 and 12 months after delivery, will be captured. In addition, data will be captured for the duration of breast-feeding, if applicable.



Follow-up duration may differ for each individual subject, depending on the outcome of pregnancy: Initial baseline information will be recorded at confirmation of pregnancy and the subject will be followed for outcome of pregnancy **and**, **if breastfeeding following a live birth, until termination of breastfeeding**. Information on pregnancy outcome, and on infant health **and development up to** 12 months after delivery, will be captured.

## Section: 9.3 Outcomes - Variables

## Replace:

9.3 Variables

Primary and secondary outcome variables include:

- Outcome Variables:
  - Congenital anomaly including congenital abnormality or malformation as defined by EUROCAT (See Appendix E for full list)
  - Complications of pregnancy including:
    - o Pre-eclampsia
    - Gestational diabetes
  - Outcomes of pregnancy: (See Appendix F for further definition):
    - Live birth
    - Elective termination (including reason, gestational age)
    - Miscarriage (including gender, anomalies, pathology)
    - Ectopic pregnancy
    - Molar pregnancy
    - o Infant(s) gender; gestational age; birth weight; Apgar score
  - Mode of delivery:
    - Normal vaginal delivery
    - o Operative vaginal delivery
    - o Caesarian section
  - Complications of delivery:
    - Abnormal cord gas
    - Abnormal fetal heart rate
    - o Abnormal amniotic fluid
    - o Blood transfusion resulting from post-partum haemorrhage;
    - $\circ$  Thromboembolism



- Exposure Variables:
  - Exposure to Repatha<sup>®</sup> (duration of exposure, doses, dose dates) within 15 weeks prior to conception and/or during pregnancy and/or whilst breast-feeding. In adult subjects a single dose of Repatha<sup>®</sup> constitutes exposure. In infants, exposure may occur in utero and/or via breast milk, within 15 weeks following the date of Repatha<sup>®</sup> dosing in the mother.
- Other Variables:
  - Baseline:
    - Country of residence; age; education; occupation; height and weight
    - Current pregnancy history (date of last menstrual period; estimated date of delivery; number of fetuses; treatment for infertility)
    - Medical history (FH diagnosis; significant comorbid conditions; family history of congenital disorders)
    - Obstetric history (number of previous pregnancies and outcome; previous maternal pregnancy complications; previous fetal/neonatal abnormalities; history of subfertility)
  - Medications (product, dose, dose dates) taken within 3 months prior to or during pregnancy (excluding medication routinely administered during labour/delivery) and/or breast-feeding
  - Lipid levels (total cholesterol, LDL, HDL, triglycerides)
  - Infant development milestones and health to 12 months of age (growth, hospitalisation, chronic medication)

Information available for each subject on all variables will be reported by study site staff in the study-specific sponsor database. The original data source will be patient records, from routine follow-up of subjects.

#### With:

#### 9.3 Outcomes - Variables

Information available for each subject on all variables will be reported by study site staff in the study-specific database held by the sponsor. The original data source will be patient (maternal – infant) records, from routine follow-up of subjects:

- Maternal Data:
  - Demographics:
    - Country of residence
    - Age (at start of pregnancy, categorized into  $\leq$  19, 20-24, 25-29, 30-34, 35-39, 40-44,  $\geq$  45 year age categories)
    - Education (highest level)



- Occupation
- Height and weight (to calculate body mass index, categorised into < 20, 20-24, 25-29, ≥ 30 kg/m<sup>2</sup> body mass index categories)
- Current pregnancy history:
  - Date of last menstrual period
  - Estimated date of delivery
  - Number of fetuses
  - Treatment for infertility
- Medical history:
  - FH diagnosis status and method of diagnosis
  - Presence of significant comorbid conditions (hypertension, diabetes mellitus, epilepsy, other)
  - Family history of congenital disorders
- Obstetric history:
  - Number of previous pregnancies and outcome
  - Previous maternal pregnancy complications
  - Previous fetal/neonatal abnormalities
  - History of subfertility
- Medications (product, dose, dose dates) taken within 3 months prior to or during pregnancy (excluding medication routinely administered during labour/delivery) and/or breast-feeding
- Lipid levels (triglycerides, total cholesterol, LDL-C, HDL-C)
- Congenital anomaly including congenital abnormality or malformation as defined by European Surveillance of Congenital Anomalies (EUROCAT) (See Appendix E for full list)
- Complications of pregnancy:
  - Pre-eclampsia
  - Gestational diabetes
- Outcomes of pregnancy: (See Appendix F for further definition):
  - Live birth (with / without congenital anomaly)
  - Neonatal death (with / without congenital anomaly)
  - Stillbirth (with / without congenital anomaly)
  - Elective termination (with / without congenital anomaly)
  - Miscarriage (with / without congenital anomaly)
  - Spontaneous abortion
  - Ectopic pregnancy
  - Molar pregnancy

- Mode of delivery:
  - Normal vaginal delivery
  - Operative vaginal delivery
  - Vaginal breech delivery
  - Caesarean section
- Complications of delivery:
  - Abnormal Cord gas
  - Fetal heart rate abnormalities
  - Abnormal amniotic fluid
  - Blood transfusion resulting from post-partum haemorrhage;
  - Thromboembolism
- Infant Data:
  - Infant status at delivery:
    - Infant(s) sex
    - Gestational age
    - o Birth weight
    - Apgar score
  - Infant outcomes until 12 months of age:
    - Weight growth
    - Developmental delay (not meeting the usual developmental milestones during the first 12 months of age)
    - Hospitalisations (total number of days hospitalised; number of hospitalisation episodes during the first 12 months)
    - Chronic medication (defined as medication prescribed for a period of 4 weeks or more)
    - Breastfeeding (date of start/stop, exclusive breastfeeding [Yes/No])
- Exposure Variables:
  - Exposure to Repatha<sup>®</sup> (duration of exposure, doses, dose dates) within 15 weeks prior to conception and/or during pregnancy and/or whilst breast-feeding. In adult subjects a single dose of Repatha<sup>®</sup> constitutes exposure. In infants, exposure may occur in utero and/or via breast milk, within 15 weeks following the date of Repatha<sup>®</sup> dosing in the mother.

Section: 9.3.1 Exposure Assessment, Paragraph 2 and 3

## Add:

Exposure to Repatha<sup>®</sup> in the 15 weeks (i.e., 5 half-lives of Repatha<sup>®</sup>) prior to or during pregnancy or breast-feeding will be entered by site staff into study-specific electronic case report forms and will be reported descriptively by dose and dates of administration. Exposure will be counted in doses of Repatha<sup>®</sup>.



The study population comprises females in Europe, South Africa and Australia diagnosed with FH and who are either pregnant or breast-feeding during the study period, and who provide informed consent to participate in the study, if applicable according to local requirements. Their infants will also be followed to the age of 12 months, following consent by the mother (if applicable per local regulations).

(Note: The therapeutic strategy assigned to each patient enrolled in the study will not be specified within this study protocol. Instead, it will be decided according to routine clinical practice, hence the decision for medicinal prescription will be clearly dissociated from the decision to include the patient in the study).

## Section: 9.5 Study Size

## Add:

In accordance with the Guideline, this study will endeavour to enrol 300 pregnancies exposed to Repatha in the first trimester in order to meet the primary objective of this study. The maximum number of unexposed pregnancies will be limited to a ratio of 2 unexposed to 1 exposed; ie, the maximum will be 600 unexposed pregnancies. In addition, the maximum of unexposed pregnancies originating from a single country will be limited to the minimum of N = 150 or tenfold the expected proportion of births out of the combined total of live births as reported by the relevant Bureaus of Statistics in the participating countries (Appendix H). For example, the observed number of live births in Norway in 2017 represented 1.5% of the births across all participating countries. Therefore, no more than N = 88 (10 x 1.5% = 15% of 600) unexposed pregnancies will originate from Norway. The observed number of United Kingdom births represents 19.6% of all 2017 live births across all countries; tenfold 19.6% of 600 would exceed the target of 600, therefore the number of unexposed pregnancies from the United Kingdom will be capped at N=150. This will ensure we enrol as many unexposed pregnancies as possible whilst avoiding that unexposed pregnancies will originate from a single country only.

## Section: 9.7.1.1 Interim Analyses

#### Replace:

## 9.7.1.1 Interim Analysis/Analyses

No formal interim analyses are planned. However, the appropriate regulatory authorities will receive:

- Interim reports of all analyses performed, to be submitted annually. (See Appendix G for the template Summary Table to be included in the report)
- A feasibility report three years after study commencement, summarising the number of subjects enrolled, any exposure to Repatha<sup>®</sup> and describing primary and secondary outcome data.

#### With:

## 9.7.1.1 Interim Analyses

The appropriate regulatory authorities will receive:

- Interim reports of all analyses performed, to be submitted annually. (See Appendix G for an example Summary Table template to be included in the report)
- A feasibility report three years after study commencement, summarising the number of subjects enrolled, any exposure to Repatha<sup>®</sup> and describing primary and secondary outcome data.

#### Section: 9.7.2.1 General Considerations, Paragraph 4

#### Add:

Multiple pregnancies, occurring in the same woman within the study period, will be reported as separate pregnancies (with an addition of a relevant footnote in the respective tables, indicating that two or more pregnancies occurred in the same woman).

## Section: 9.7.2.2 Missing or Incomplete Data and Lost to Follow-up

#### Replace:

For all study-related parameters, data are recorded as part of pregnancy follow-up in this cardiovascular high risk population, and a high degree of completeness of follow-up and data recording can be expected. Proactive follow-up will also be encouraged.

There will be no imputation for missing data.



For all study-related parameters, data are recorded as part of pregnancy follow-up in this cardiovascular high-risk population, and a high degree of completeness of follow-up and data recording can be expected. However, the necessity of obtaining data from multiple sources may incur an increased risk of being unable to obtain specific sets of patient notes. Proactive follow-up will also be encouraged.

There will be no imputation **of** missing data.

Section: 9.7.2.4 Analysis of the Primary and Secondary Endpoints

## Replace:

Analysis of Primary Objective:

Congenital anomalies will be summarised and descriptive statistics will be presented.

Congenital anomalies will be defined according to ICD10-BPA codes.

Analyses of Secondary Objectives:

Secondary objective outcome measures will be summarised and descriptive statistics will be presented.

For all analyses, outcomes of Repatha<sup>®</sup>-exposed pregnancy in women with FH (and their infants) and enrolled into this study may be compared to:

- Outcomes in women with FH (and their infants) with pregnancies not exposed to Repatha<sup>®</sup> and enrolled into this study, overall and stratified by lipid lowering therapy use
- Outcomes documented in existing data sources which may include: A female heterozygous FH population in Norway; European teratology information centres; the general population in the EU; a systematic review of the literature to capture any additional published pregnancy outcome rates in the population of interest.

#### With:

Analysis of Primary Objective:

Congenital anomalies will be summarised and descriptive statistics will be presented.

Congenital anomalies will be defined according to ICD10-BPA codes (codes included

in Appendix E: EUROCAT Subgroups of Congenital Anomalies).



Analyses of Secondary Objectives:

Secondary objective outcome measures will be summarised and descriptive statistics will be presented.

Due to potentially insufficient data and consequent lack of statistical power, it is unlikely that comparisons between the 2 groups will provide meaningful results, hence, no formal comparison of exposed/unexposed subjects is planned.

#### Section: 9.7.2.7 Stratified Analysis

#### Replace:

Analyses will be stratified according to exposure to Repatha<sup>®</sup> (in the 15 weeks prior to conception or in the first trimester of pregnancy, in the second or third trimester of pregnancy, and/or whilst breast-feeding), vs unexposed, and by exposure to other lipid modifying therapies (including statins, PCSK9 inhibitors, CETP inhibitors, and others).

#### With:

For the secondary objective of describing health and developmental outcomes in infants up to 12 months of age, analyses will be stratified according to whether the infant was exposed to Repatha<sup>®</sup> (in the 15 weeks prior to conception or in the first trimester of pregnancy, in the second or third trimester of pregnancy, and/or whilst breast-feeding). In addition, a stratified analysis will be conducted by exposure to other lipid modifying therapies (including statins, PCSK9 inhibitors, CETP inhibitors, and others).

In addition, data obtained from retrospective and prospective subject identification will be reported separately (to account for the possibility that subjects enrolled retrospectively may differ from those enrolled prospectively).

Results from mothers are to be presented using the following columns: (i) 'unexposed', (ii) 'exposed but stopped prior to conception', (iii) 'exposure in 1<sup>st</sup> trimester (up to 15 weeks)', (iv) 'exposure in 2<sup>nd</sup>/3<sup>rd</sup> trimesters', (v) 'exposed at conception and during 1<sup>st</sup> trimester but stopped during 2<sup>nd</sup>/3<sup>rd</sup> trimesters, (vi) 'exposed throughout pregnancy', (vii) 'exposure during breastfeeding only', and (viii) 'exposure anytime during pregnancy and up to 15 weeks, and breastfeeding'. Columns will not be mutually exclusive.



## Replace:

Information bias is unlikely, as the key outcome measures are objective and the primary outcome measure will be independently adjudicated. There is no reason to anticipate any differential in the reporting of outcomes between exposed and unexposed subjects enrolled into the study.

## With:

Information bias may occur from participants who are recruited retrospectively more likely to have adverse outcomes. This will occur because participants with adverse outcomes will make the clinician consider recruiting them.

Section: 9.9.2 Selection Bias, Paragraph 2

## Add:

Selection bias may occur due to pregnant women without adverse outcomes potentially being less likely to be told about the study, or less inclined to participate in the study. To help to minimise selection bias arising from preferential enrolment of subjects experiencing adverse outcomes rather than those with normal outcomes, sites will be requested to enrol all eligible patients whether retrospectively or prospectively identified, and regardless of outcomes which are already known.

Section: 9.9.3 Limitations due to Missing Data and/or Incomplete Data

## Add:

# Although the necessity of obtaining data from multiple sources may incur an increased risk of being unable to obtain specific sets of patient notes,

**m**issing/incomplete data is unlikely to be a limitation for subjects identified and enrolled into this study, as physicians treating FH women pay particular attention to their clinical management during pregnancy and breast-feeding. It is not expected that information on outcomes will be missing, due to the critical nature of follow-up of pregnant women and their infants regardless of an adverse or a normal outcome. Additionally, Amgen will review all study data thoroughly and will follow up directly with study sites to query for missing information.



## Section: 10.1 Informed Consent, Paragraph 1

## Add:

An initial sample informed consent form is provided for the Investigator to prepare the informed consent document to be used at his or her site, **according to local regulations**. Updates to the template are to be communicated formally in writing from the Amgen Clinical Study Manager to the Investigator. The written informed consent document is to be prepared in the language(s) of the potential subject population.

Section: 11 Collection of Safety Information and Product Complaints, Paragraph 2

## Add:

For subjects known to be exposed to Repatha<sup>®</sup> within the 15 weeks prior to or during pregnancy and/or during breastfeeding, a Pregnancy Notification Worksheet and/or Lactation Notification Worksheet (Appendix H), as appropriate, is to be submitted to Amgen and will be collected until termination of breastfeeding, otherwise until **12 months post-partum**.

Section: 11.2 Safety Reporting Requirements, Paragraph 1 and 2

## Replace:

The Investigator is responsible for ensuring that safety events (adverse events, product complaints and other safety findings) observed by the Investigator or reported by the subject that occur during the observation period through to the final study contact are recorded in the subject's appropriate study documentation. Safety events must be submitted as individual case safety reports to Amgen via the applicable Amgen Safety Reporting Form (paper or electronic form) within 1 business day of Investigator awareness.

## With:

The Investigator is responsible for ensuring that safety events (adverse events, product complaints and other safety findings) observed by the Investigator or reported by the subject that occur during the **study** observation period are recorded in the subject's appropriate study documentation. The observation period for this study consists of 2 distinct periods: 1) the retrospective observation period that is defined as the time between diagnosis of pregnancy and the subject's enrolment into the study and, 2) the prospective observation period defined as the time between subject's enrolment date until the end of her and the infant's follow-up.



For safety events that occurred in the retrospective observation period, the date on which the investigator accessed the subject's medical charts to abstract the relevant retrospective information should be entered into the field "Date Investigator became aware of this Event" on the Event eCRF. Safety events identified in both the retrospective and prospective period must be submitted as individual case safety reports to Amgen via the applicable Amgen Safety Reporting Form (paper or electronic form) within 1 business day of Investigator awareness.

Non-serious adverse events must be reported in an expeditious manner, not to exceed 15 calendars days of investigator awareness.



# Section: 15 Appendices, Appendix G, Template Summary Table of Pregnancy Outcome

# Replace:

Pregnancy outcome	Prospective cases				Retrospective cases						
	Number					Number					
	Timing of exposure in pregnancy						Timing of exposure in pregnancy				
	Before conception	l <sup>st</sup> trimester	After 1 <sup>st</sup> trimester	During all pregnancy	Unknown	Before conception	l <sup>st</sup> trimester	After 1 <sup>st</sup> trimester	During all pregnancy	Unknown	
Ectopic pregnancy											
Spontaneous abortion											
Elective termination (foetal defects)			•								
Elective termination (no foetal defects or unknown)											
Stillbirth with foetal defects											
Stillbirth without foetal defects											
Live birth with congenital anomaly											
Live birth without congenital anomaly											
Total											

	Timing of Repatha <sup>®</sup> exposure								
	Unexposed (N = x) n (%)	Exposed but stopped prior to conception (N = x) n (%)	1st	n Exposure in 2 <sup>nd</sup> /3rd trimesters (N = x) n (%)	Exposed at conception and during 1 <sup>st</sup> trimester but stopped in 2nd/3rd trimesters (N = x) n (%)	Exposed	Exposure during breastfeeding only (N = x) n (%)	Exposure during both pregnancy and breastfeeding (N = x) n (%)	
Pregnancies enrolled pre-partum									
All outcomes	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	
Live birth without congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	
Live birth with congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	
Neonatal death without congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	
Neonatal death with congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	
Stillbirth without congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	
Stillbirth with congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	
Miscarriage without congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	
Miscarriage with congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	
Termination of pregnancy without congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	
Termination of pregnancy with congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	
Ectopic pregnancy	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	
Molar pregnancy	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	
Pregnancy continuing at time of data cut-off	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	
Pregnancies enrolled post-partum	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	
All outcomes	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	
Live birth without congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	
Live birth with congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	
Neonatal death without congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	
Neonatal death with congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	



			٦	liming of Re	oatha <sup>®</sup> expos	ure		
	Unexposed (N = x)	Exposed but stopped prior to conception (N = x)	Exposure ir 1st trimester (N = x)	n Exposure ir 2 <sup>nd</sup> /3rd trimesters (N = x)	Exposed at conception and during 1 <sup>st</sup> trimester but stopped in 2nd/3rd trimesters (N = x)	Exposed	Exposure during breastfeeding only (N = x)	Exposure during both pregnancy and breastfeeding (N = x)
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Stillbirth without congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Stillbirth with congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Miscarriage without congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Miscarriage with congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Termination of pregnancy without congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Termination of pregnancy with congenital anomaly	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Ectopic pregnancy	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)
Molar pregnancy	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)	x (x.x)

## Section: 15 Appendices, Appendix H, Calculation of Percentage of Live Births

Add:

Country	Live Births (2017)	% of Total live births	Expected N live births of unexposed mothers	Country cap on unexposed pregnancies	
Australia	309,142	8.0	48	150	
Austria	87,633	2.3	14	136	
Belgium	119,690	3.1	19	150	
Czech Republic	114,405	3.0	18	150	
Denmark	61,397	1.6	10	95	
Greece	88,523	2.3	14	138	
Italy	458,151	11.9	71	150	
Netherlands	169,200	4.4	26	150	
Norway	56,633	1.5	9	88	
Slovakia	57,969	1.5	9	90	
South Africa	989,318	25.6	154	150	
Spain	390,024	10.1	61	150	
Sweden	115,416	3.0	18	150	
Switzerland	87,381	2.3	14	136	
UK	755,043	19.6	117	150	
Total	3,859,925	100.0	600	NAª	

Appendix H. Calculation of Percentage of Live Births

Sources:

Eurostat (2018) Live births and crude birth rate: https://ec.europa.eu/eurostat/tgm/table.do?tab=table&init=1&language=en&pcode=tps00204&plugin=1 Australian Bureau of Statistics (2018) Births, Australia, 2017:

http://www.abs.gov.au/ausstats%5Cabs@.nsf/0/8668A9A0D4B0156CCA25792F0016186A?Opendocument

Statistics South Africa (2018) Recorded live births, 2017. http://www.statssa.gov.za/?p=11478 Footnote:

<sup>a</sup> maximum number of unexposed pregnancies will be capped at 600 across all countries, therefore a minimum of 4 countries will be represented among unexposed pregnancies

